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I. Introduction: Pigment Epithelium Derived Factor (PEDF) 
PEDF is a multifunctional protein with relevant clinical potential. To date, 
the protein has been described to have antiangiogenic, neuroprotective and 
antivasopermeability properties. It has also been proven to have differentiating 
activity for certain neurons, as well as tumor cells.  
I.1. The gene 
PEDF is a member of the serine protease inhibitor (SERPIN) super gene 
family (Steele et al., 1993). Southern blot analysis indicates that there is only one 
splicing form for the mouse and human gene (Singh et al., 1998; Tombran-Tink 
et al., 1996). The gene is particularly conserved among primate species, but 
PEDF sequences have been identified in mammals, birds, amphibians and fish, 
while no hybridization signals could be detected in lower species such as 
Drosophila and Caenorhabditis elegans (Tombran-Tink et al., 1996).  The human 
gene spans about 16kb and has 8 exons and 7 introns (see Fig. I.1.1). While the 
intron-exon organization of PEDF is highly conserved in all investigated species, 
the intron size considerably varies even within mammals (Barnstable and 
Tombran-Tink, 2004). The genomic structure of the PEDF gene suggests that 
PEDF is part of the ovalbumin family of serpins to which ovalbumin and 
plasminogen activator inhibitor also belong. Like most other serpins, the first 
exon is non-coding. Structurally, the PEDF gene is rather different from glia-
derived nexin/protease nexin-1, the only other serpin with known neurotrophic 
activity (Tombran-Tink et al., 1996).         
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Fig. I.1.1. Full length sequence of the mouse PEDF cDNA as shown by Singh 
(1998). 
The sequence was obtained from a mouse liver cDNA clone. Exons are labeled 
and untranslated sequences are shown in lower case while coding regions are in 
upper case letters. The amino acids are shown in single letter code above the 
second base of the codon. GenBank accession number AF017057. 
 
The gene has been mapped to the short arm of human chromosome 
17p13.3 (Tombran-Tink et al., 1994; Goliath et al., 1996) and is tightly and 
probably also functionally linked to the locus RP13 for Retinitis Pigmentosa, an 
inherited retinal degeneration (Goliath et al., 1996; Cayouette et al., 1999). 
Although deletion of 17p is the most frequent abnormality observed in primitive 
neuroectodermal tumors of the central nervous system (CNS), no mutations of 
the PEDF gene have been associated with these tumors (Slavc et al., 1997). 
However, complete or allelic loss of PEDF in knockout animals was found to be 
associated with aggressive metastatic tumors (Doll et al., 2003; Guan et al., 
2004). 
Contrary to the strong conservation of the coding sequences of the gene 
among species, available data indicate that there is only limited homology among 
species in their promotor regions (Singh et al., 1998). The PEDF promoter 
contains a functional retinoic acid receptor element and PEDF gene expression 
has been shown to be controlled by all-trans-retinoic acid in cell types of various 
origin (Tombran-Tink et al., 2004). The PEDF gene is strongly expressed in 
differentiated retinal pigment epithelial (RPE) cells of the retina and barely 
detectable in undifferentiated RPE cells (Ohno-Matsui et al., 2001). Similarly, a 
loss of PEDF expression has been found in glioma progression and is associated 
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with the degree of differentiation of glioblastoma and neuroblastoma (Guan et al., 
2003; Crawford et al., 2001). Furthermore, PEDF gene expression is high in 
quiescent (G0) and actively dividing young cells (Pignolo et al., 1993 and 2003; 
Tombran-Tink et al., 1995), but low in senescent cells of various origins (Pignolo 
et al., 1993 and 2003; Tombran-Tink et al., 1995), so that PEDF has also been 
called early population doubling cDNA-1 (EPC-1). PEDF has been therefore 
suggested to play a role in the entry of young cells into the G0 state or the 
maintenance of this state once reached. There is some evidence that the decline 
of PEDF gene expression in senescent cells involves a change in stability of the 
PEDF RNA and that this occurs at the posttranslational level (Coljee et al., 2000). 
 
I.2.The protein 
Serpins are a protein family with similar, basic globular structure, but wide 
functional diversity. Human PEDF is a 46-50 kDa monomeric glycoprotein of 418 
amino acids (see also Fig. I.1.1.) that was first purified from the conditioned 
medium of human retinal pigment epithelial (RPE) cells as a factor that induces 
neuronal differentiation of cultured Y-79 retinoblastoma cells (Tombran-Tink and 
Johnson, 1989; Tombran-Tink et al., 1991). Although PEDF belongs to the serine 
protease inhibitor (SERPIN) super gene family (Steele et al., 1993), no inhibitory 
effect on serine proteases has been found (Becerra et al., 1995; Becerra, 1997). 
Furthermore, residue position 78-121 (44-mer) that lacks the homologous serpin-
reactive loop retains its neuronal differentiation, survival, anti-angiogenic and 
anti-vasopermeability activities (Becerra et al., 1995; Araki et al., 1998; Dawson 
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et al., 1999; Liu et al., 2004). Analysis of the crystal structure of the PEDF protein 
has shown that the distribution of the surface charge is of striking asymmetric 
distribution and is thought to be of physiological relevance (Fig. I.2.1) (Simonovic 
et al., 2001). Interestingly, the N-terminal of the bioreactive 44-mer is buried in 
the protein and the C-terminal forms an exposed loop with a cleft (Barnstable and 






Fig.I.2.1 Crystal structure of PEDF as shown in Barnstable and Tombran-Tink 
(2004). 
(A) A space filling model of human PEDF showing a cluster of positive charges 
(blue) on one side of the molecule and a cluster of negative charges (red) on the 
other side of the molecule (B). These charged groups are thought to interact with 
extacellular matrix molecules. (C-E) The 44-mer peptide shown within the whole 
PEDF molecule (C), its polypeptide backbone (D) and with the amino acid side 
chains (E). 
 
Thus far, there are several posttranslational modifications of PEDF, one of 
which has been shown to change the function of the protein (Fig. I.2.2). 
Extracellular phosphorylation of PEDF at Ser 24 and 114 by protein kinase CK2 
abolishes its neurotrophic activity and enhances the antiangiogenic effect, while 
intracellular phosphorylation at Ser 227 by protein kinase A reduces its 
antiangiogenic activity (Maik-Rachline et al., 2004). Furthermore, PEDF has been 
reported to carry one N-linked glycosylation at Asn 266. Depending on the type 
of tissue in which it is produced, the N-terminal can be modified to pyroglutamate 
and is therefore blocked to Edman degradation (Wu et al., 1995; Wu and 
Becerra, 1996; Petersen et al., 2003). 
 
 
Fig.I.2.2 Adjusted schema from Petersen et al. (2003), depicting the post-
translational modifications of PEDF. 
The open bar represents mature PEDF. The reactive center loop (RCL) of the 
serpin structure is indicated. The N-terminal can be modified to a pGlu and Asn 
266 can be glycosylated with or without a core fucosilation. In the blood, the 
sulfhydryl group Cys-242 is free. Ser 24 and 114 can be phosphorylated by 
protein kinase CK2, while protein kinase A phosphorylates Ser 227.  
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I.3. Binding of PEDF 
To date, no distinct receptor for PEDF has been found and it is not well 
understood how PEDF exerts its various effects. There are indications that the 
different functions of PEDF as angiogenic inhibitor and neuroprotective agent 
may be mediated by PEDF binding molecules/receptors of different size. Thus 
far, a PEDF-binding molecule of about 80-85kDa has been shown in 
retinoblastoma Y79 and cerebellar granule cells (Alberdi et al., 1999). The 
binding of PEDF to Y79 (Kd=3nM) and cerebellar granule cells (Kd=4.5nM) was 
saturable and specific to a single class of binding molecules with similar affinities. 
A putative receptor binding site of PEDF protein has been predicted to include 
the exposed parts of helices C and D and loop 90 (Fig. I.3.1; Simonovic et al., 
2001). PEDF was also found to bind to motor neurons (Kd=2.4-18.9nM) and 
bovine retinal cells (Kd=6.5nM) with similar binding affinity (Bilak et al., 2002; 
Aymerich et al., 2001), suggesting a homologous protein for the PEDF receptor 
in these neuronal systems. Pericytes surrounding the vasculature were however 
shown to have a 62 kDa PEDF binding protein with a dissociation constant of 
7.46 nM, which also suggests an interaction with a cellular receptor (Yamagishi 
et al., 2002). However, it is still not clear whether these proteins are a receptor or 
a regulatory binding protein that controls the function of PEDF.                                                                                                                                                                                                                    
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Fig. I.3.1. Crystal structure of the putative receptor binding site of PEDF as 
shown by Simonovic (2001).  
A) A GRASP representation with basic (blue) and acidic (red) side chains and B) 
stereo view. The binding site based on peptide studies is in magenta with its 
secondary structure elements displayed as ribbons.  
 
The secreted protein has also been found to bind to extracellular matrix 
components such as collagen type I and III, heparin, chondroitin sulfates and 
dextran sulfates in an ionic fashion (Alberdi et al., 1998; Meyer et al., 2002; 
Kozaki et al., 1998). There is evidence that binding of PEDF to collagen is critical 
for its antiangiogenic activity (Hosomichi et al., 2005). It was suggested that the 
heparin and proteoglycan-binding sites are located at the basic surface of PEDF 
(see Fig. I.2.1). The bioreactive peptide within the protein that confers the 
neurotrophic function of PEDF is distinct and nonoverlapping from the serpin 
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exposed loop and the glycosaminoglycan binding site, which are located on 
opposite sides of the protein (Alberdi et al., 1998).  
 
I.4. Localization and protein expression  
PEDF protein has been originally localized in the interphotoreceptor matrix 
of eyes of various species (Becerra et al., 2004; Behling et al., 2002, Karakousis 
et al., 2001; Ogata et al., 2002, Ortego et al., 1996; Wu et al., 1995) and exists in 
basically all compartments of the eye. Apart from the eye, PEDF protein is 
present in various other organs, biological fluids (vitreous, serum and 
cerebrospinal fluid (CSF)) and the CNS. However, due to the fast secretion of 
PEDF, it has been difficult to localize the protein in certain conditions (Kozaki et 
al., 1998).  PEDF mRNA has been found in nearly all adult human organs 
including the eye, liver, bone marrow, kidney, pancreas, lung, appendix, heart, 
muscles, placenta, small intestine, colon, stomach, ovary, testis, various brain 
regions (Tombran-Tink et al., 1996) and several types of blood cells (unpublished 
data from our laboratory; see Fig. V.1.1.). However, it is not known if cells of 
these organs in fact produce the PEDF protein or just bind PEDF and which cells 
of these organs exactly produce and respond to PEDF.  
The protein has been also detected in tissues of the embryonic mouse 
that are rich in collagen I and III, such as teeth, bone, skin and smooth muscle 
layers of aorta, esophagus and so forth, but not in embryonic brain (Kozaki et al., 
1998). There are also conflicting reports about the immunohistochemical 
detection of PEDF in embryonic mouse liver (Kozaki et al., 1998; Sawant et al., 
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2004). In the CNS, thus far PEDF immunoreactivity has been reported only in 
motor neurons of the ventral horn in the adult human, monkey and rat spinal 
cord, as well as in ependymal cells (Bilak et al., 1999 and 2002).  
 
I.5. Biological functions  
PEDF has been described to have multiple functions. There is plenty of 
evidence that PEDF serves as a neuroprotective factor for various cells of the 
CNS (Taniwaki et al., 1995 and 1997; Araki et al., 1998; DeCoster et al., 1999; 
Houenou et al., 1999, Bilak et al., 1999 and 2002) which will be described in 
more detail later on. PEDF has been also reported to have differentiating activity 
for several tumor cells, but also some neuronal cells (Houenou et al., 1999; 
Crawford et al., 2001; Tombran-Tink and Johnson, 1989). Furthermore, PEDF is 
a potent antiangiogenic factor that controls the growth of new blood vessels in 
normal and pathological conditions which will also be discussed in more detail in 
chapter IV (Tombran-Tink and Barnstable, 2003; Dawson et al., 1999; Mori et al., 
2001; Stellmach et al., 2001; Duh et al., 2002). As an antiangiogenic agent, 
PEDF has been proven to inhibit tumor growth by suppressing tumor 
vascularisation of various organs (Abe et al., 2004; Mahtabifard et al., 2003; 
Wang et al., 2003, Abramson et al., 2003). There are also indications that PEDF 
may have antivasopermeability function (Liu et al., 2004). It has been even 
speculated that PEDF may play a role in wound healing (Peterson et al., 2003), 
as well as in organogenesis or morphogenesis (Kozaki et al., 1998). 
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I.5.1. PEDF in the eye  
PEDF protein is located in various cell types of the human, monkey, 
bovine, mouse and rat retina, (Behling et al., 2002, Karakousis et al., 2001; 
Ogata et al., 2002, Ortego et al., 1996; Wu et al., 1995) and was shown to exist 
in basically all compartments of the eye, including the vitreous, RPE, retina, 
choroid, ciliary body, lens and cornea (Fig. I.5.1.1). Lens and cornea are thought 
to be the source of PEDF secretion into the vitreous and aqueous humor (Ogata 
et al., 2002).  
 
           
Fig. I.5.1.1 Schematic diagram of the eye as shown in Bouck, 2002.  
Avascular tissues are shown in gray and well vascularised tissues in pink/red. 
 
 
It has been shown that PEDF has differentiating effects on various retinal 
cell types (Jablonski et al., 2000 and 2001) including the differentiation of albino 
RPE cells from Wistar rats and the maturation of their pigment granules 
(Malchiodi-Albedi et al., 1998). There is also evidence that PEDF protects 
various cell types of the rat retina from different toxic conditions including 
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phototoxicity, hydrogen peroxide toxicity and ischemic conditions (Cao et al., 
1999 and 2001; Ogata et al., 2001a).  
Besides its neuroprotective effect, PEDF is one of the most potent natural 
inhibitors of angiogenesis in the eye (Dawson et al., 1999; Tombran-Tink and 
Barnstable, 2003). The protein inhibits the migration of retinal endothelial cells in 
vitro (Duh et al., 2002) and induces apoptosis of endothelial cells that are 
participating in neovascularisation, but does not harm existing vessels (Stellmach 
et al., 2001). PEDF is probably responsible for the normal avascularity of several 
ocular compartments and loss of its expression leads to increased ischemia-
induced retinal neovascularisation (Dawson et al., 1999). Treatment of mice with 
systemic or intra-ocular injections of recombinant PEDF results in a significant 
decrease of choroidal and retinal neovascularisation (Mori et al., 2001; Stellmach 
et al., 2001; Duh et al., 2002).  
 
PEDF has been shown to play a role in many eye diseases. Thus, the 
levels of PEDF in the aqueous humor or vitreous of patients with various 
degenerative eye diseases have been shown to be decreased, such as in 
choroidal neovascularisation in age related macular degeneration (AMD) 
(Holekamp et al., 2002), in proliferative diabetic retinopathy and in Rubeosis 
(Spranger et al., 2001; Boehm et al., 2003a and b), as well as in retinis 
pigmentosa and glaucoma (Ogata et al., 2001b). PEDF was found to transiently 
delay the death of photoreceptors cells in the rd/rd and rds/rds mouse models of 
retinitis pigmentosa (Cayouette et al., 1999), furthermore indicating its 
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association with this disease. Increased PEDF concentrations have only been 
found in rhegmatogeneous retinal detachment, where PEDF was speculated to 
act as a neuroprotective agent for the detached retina (Ogata et al., 2001b and 
2002). 
 
I.5.2. PEDF/VEGF relation in the eye 
Vascular Endothelial Growth Factor (VEGF) and PEDF share many similar 
activities. Both growth factors are neurotrophic and neuroprotective, and control 
vascular permeability and angiogenesis. In the healthy adult eye and most other 
healthy tissues, no new vessels are being formed due to a finely tuned balance 
of pro- and antiangiogenic factors. In conditions such as ischemia and 
oncogenesis this balance is disturbed and leads to neovascularisation.  
VEGF is a major mediator of vascularisation in the eye and other tissues 
and plays an essential role in the development and maintenance of neuronal 
tissue in the retina (Robinson et al., 2001). But VEGF has been also shown to be 
a key angiogenic factor in various pathogenic conditions, such as diabetic 
retinopathy, retinopathy of prematurity and cancer, and initiates angiogenesis by 
promoting endothelial cell proliferation (Alon et al., 1995).  
Most ocular angiogenesis is caused by low oxygen levels resulting into 
ischemia which have been shown to stimulate the production of angiogenic 
inducers including VEGF (Keshet, 2001; Gao et al., 2001, Ohno-Matsui et al., 
2001). Hypoxia stemming from prolonged diabetes causes retinal vessels to 
grow into the vitreous and eventually threaten sight (Klein et al., 1994). In older 
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adults with AMD, vessels in the choroid can grow into and under the retina where 
they can cause vision loss (Fine et al., 2000). Recently, it has been shown that 
oxygen levels also control the production of PEDF. When oxygen levels are high, 
PEDF production rises in cultured cells and retinal tissue, and when oxygen 
levels are low, PEDF production decreases (Dawson, 1999; Gao et al., 2001, 
Ohno-Matsui et al., 2001). Although it is clear, that there are various factors 
involved in retinal neovascularisation, it has been suggested that an unbalanced 
ratio of VEGF to PEDF is associated with different conditions leading to 
pathological neovascularisation (Gao et al., 2001; Tombran-Tink and Barnstable, 
2003), and the reason for the high sensitivity of some rat strains to 
neovascularisation after hyperoxia (Fig. I.5.2.1; Gao et al., 2002a). However, it is 
not known how PEDF influences the signaling cascade of VEGF or whether 




          
 
Fig. I.5.2.1. Schematic drawing of different stages of angiogenesis balance as 
shown in Gao and Ma, 2002. Abbreviations: bFGF, basic fibroblast growth factor; 
IGF, insuline-like growth factor;  
 
 
I.5.3. PEDF in the brain  
Several studies provide evidence that PEDF does not only have 
neuroprotective effects on various cell types of the eye, but also on other cells in 
the CNS (Barnstable and Tombran-Tink 2004). The neurotrophic effect of PEDF 
on cells of the brain has been demonstrated mainly by in vitro experiments by its 
ability to support neuronal survival, to protect neurons against various neurotoxic 
effects and in some cases to induce neuronal differentiation. So far, it has been 
shown that PEDF has survival and/or differentiating effects on primary cultures of 
rat cerebellar granule neurons (Taniwaki et al., 1995 and 1997; Araki et al., 
1998), immature primary rat hippocampal neurons (DeCoster et al., 1999), and 
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avian and murine spinal motor neurons (Houenou et al., 1999, Bilak et al., 1999 
and 2002). Furthermore, the degree of PEDF protein expression has been 
inversely linked with the malignancy of glioma and neuroblastoma (Guan et al., 
2003; Crawford et al., 2001) 
 
To date, there is very little evidence that PEDF protein is produced in cells 
of the brain, although PEDF mRNA was found in tissue homogenates of various 
human brain areas (Tombran-Tink et al., 1996). In support of the hypothesis that 
PEDF may be produced by cells of the CNS is the finding that PEDF protein was 
proven to exist in CSF (Bilak et al., 1999; Kunck et al., 2002) and is produced by 
Schwann cells (Crawford et al., 2001). So far, the only immunohistochemical 
data that might indicate the expression of PEDF protein in the healthy CNS was 
shown for human, monkey and rat motor neurons and ependymal cells of the 
spinal cord (Bilak et al., 1999 and 2002).   
 
I.6. Signal transduction of PEDF 
To date, there is very little evidence how PEDF exerts its neuroprotective and 
differentiating effects, as well as its antiangiogenic and antipermeability function. 
Thus far, three different possible signaling pathways have been identified that are 
known to regulate pathways that are involved in the control of cell survival, 
proliferation and cell death (Fig. I.5.3.1). One pathway was discovered in 
cerebellar granule cells, where the neuroprotective effect of PEDF is mediated by 
the phosphorylation of IĸB, which is an inhibitor of nuclear factor ĸB (NFĸB), 
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thereby leading to the activation and translocation of NFĸB to the nucleus and 
transcription of anti-apoptotic and neuroprotective genes (Yabe et al., 2001). 
Interestingly, in neonatal astrocytes PEDF induces the activation of several 
proinflammatory genes through the activation of NFĸB, AP-1-DNA and CREB, 
indicating that the activation of the same transcription factor can induce a 
different set of genes in different cell types. A second pathway was found in 
endothelial cells. PEDF controls the proliferation of these cells only under certain 
growth conditions and activates the mitogen-activated protein kinase (MAPK) 
pathway by regulating the phosphorylation of extracellular-signal-regulated 
kinase (ERK) 1 and 2 (Hutchings et al., 2002). The third PEDF-induced pathway 
is the Fas-Fas ligand death cascade which was shown to be activated by PEDF 
in endothelial cells and is associated with the antiangiogenic effect of PEDF 
(Volpert et al., 2002). However, there are indications that PEDF has additional 
inhibitory actions in endothelial cells since PEDF still is able to inhibit 
angiogenesis in Fas or FasL deficient mice (Barreiro et al., 2003).  
Thus, many questions remain unanswered about the signaling cascade of 
PEDF such as if PEDF activates or permits crosstalk with parallel transduction 
cascades, and if there are different responses to activation of a single pathway, 
or if there are developmentally regulated PEDF signals and responses 





Fig. I.5.3.1 Intracellular transduction pathways activated by PEDF as shown in 
Barnstable and Tombran-Tink, 2004.  
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II. Aim of study 
II.1. PEDF in the eye  
Objective 1:  
Since PEDF has been shown to induce the maturation and pigmentation of RPE 
cells of albino Wistar rats in vitro, it will be addressed if albino Wistar and 
pigmented Long Evans rats differ regarding their PEDF protein content and 
localization. For that purpose the two rat strains are compared in their PEDF 
expression and immunolocalization from birth until young adulthood.  
 
Objective 2:  
In order to investigate if a change in the PEDF protein expression might be 
related to the observed retinal degeneration, old albino Wistar rat eyes and 
retinas with retinal degeneration will be compared to morphologically intact age 
matched Long Evans eyes in regard to their PEDF content and localization. This 
question is addressed since old Wistar eyes show signs of retinal degeneration 
that resemble those of AMD (Sullivan et al., 2002) and choroidal 
neovascularisation in humans, which are the most common cause for severe 
visual loss of older patients in developed countries (Fine et al., 2000). 
 
Objective 3:  
The relation of PEDF and VEGF protein expression and localization during 
normal physiological angiogenesis of the rodent eye will be determined from birth 
until young adulthood. This is to test the hypothesis that during normal 
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physiological angiogenesis angiogenic stimulators outweigh angiogenic inhibitors 
similarly as during times of pathological neovascularisation, when the balance 
between VEGF and PEDF protein expression is disturbed. 
 
Objective 4:  
To determine if the VEGF/PEDF ratio changes during postnatal development and 
during pathological degeneration and neovascularisation of Wistar eyes at old 
age, old albino Wistar eyes are compared to age matched pigmented Long 
Evans eyes regarding their VEGF and PEDF content and expression.  
 
II.2. PEDF in the brain 
So far, the main research has focused on the antiangiogenic effect of PEDF in 
the eye where PEDF was originally found. However, very little is known about the 
localization of PEDF in the brain.  
 
Objective 1:  
In order to find out whether PEDF protein is produced by, or bound to particular 
cells in the brain, the question is addressed if PEDF can be located in the adult 
rat brain by immunohistochemical means.  
 
Objective 2:  
The question to be addressed will be which cell types in the adult rat brain are 
immunopositive for PEDF.  
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Objective 3:  
To test if age affects the PEDF protein production or binding of PEDF within the 
brain, the overall PEDF content of the brain, as well as PEDF serum content will 
be tested at various pre- and postnatal ages, and the PEDF immunolocation will 
be determined at various times during postnatal development. 
 
III.3. Posttranslational modification of PEDF 
PEDF is a multifunctional protein. It has been shown that depending on the type 
of posttranslational modification of the protein the function of PEDF can change.  
 
Objective 1:  
To test if age affects the glycosylation status of PEDF, this work addresses the 
question whether the posttranslational glycosylation of PEDF changes during 
postnatal development of the eye. 
 
Objective 2:  
To test if the glycosylation status varies between secreted and intracellular PEDF 
and if it is tissue specific, it will be investigated whether the glycosylation degree 





Objective 3:  
To investigate whether the differentiation status affects the glycosylation status of 
PEDF, it will be tested if the degree of glycosylation changes between 
differentiated and undifferentiated cells.  
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Accutase         Innovate Cell Technologies, USA
B27 supplement                                             Gibco BRL, Germany
Collagen type I                                                 Sigma, Germany
DABCO (1,4-diazabicyclo(2,2,2)octane) Sigma, Germany
Dispase II                                                           Boehringer Mannheim 
Dialyzed fetal calv serum (dFCS)                 PAA, Germany 
DNase I                                                            Worthington Biochemicals 
DMEM high glucose Bio Whittaker
DMEM/F12                                                     Boehringer, Germany
Dulbecco’s phosphate buffered saline  (PBS)        Sigma, Germany
Epidermal Growth Factor  (EGF)                            R&D Systems 
Fibroblast growth factor (FGF)                  R&D Systems 
FCS       PAN, Germany
Fungizione   PAA, Germany 
Glutamax   Gibco BRL, Germany
Glutamin Sigma, Germany
Glycerol Merck, Germany
Heparin                                                                   Sigma, Germany
Hanks balanced salt solution without Mg/Ca            PAN, Germany
Hiberante A                                                   Gibco BRL, Germany
Laminin  Sigma, Germany
N2 supplement                                         Gibco BRL, Germany





Recombinant N-glycosidase F                                                   Roche, Germany
Sialidase/Neuraminidase from Roche, Germany




AEBSF(Aminoethylbenzenesulfonyl Fluorid) Sigma, Germany
Acrylamid BioRad
Bio-Rad DC protein assay                                                     Hercules, CA 
Chemoluminescent ECL detection reagent       Amersham Biosciences, England
Complete protease inhibitor cocktail tablets                        Roche, Germany
Human recombinant PEDF                        BioProducs, USA 
Hyperfilm    Amersham Biosciences, England
Mercaptoethanol Sigma, Germany
Nitrocellulose membrane Protran                                            Schleier&Schuell, Germany
Ponceau S Sigma, Germany
Precision Plus Protein Standard         BioRad
Restore Western Blot stripping         Pierce
Tris-Glycine SDS Buffer  BioRad
Tween 20        Sigma, Germany
III.1.4. Immunodetection
Chemical Source
Avidin-biotin complex, Vector stain ABC-HRP Vector Laboratories, USA
Bovine serum albumin (BSA) PAA 
DAB (3,3'diaminobenzidinetetrahydrocholrid)                      Vector Laboratories, USA
Goat preimmune IgG                       Sigma, Germany
Human recombinant PEDF                        BioProducs, USA 
Hydrogen peroxide Merck, Germany 
2-Methylbutane Aldrich, Germany
Mouse IgG Sigma, Germany
Neo-Mount mounting medium                            Merck, Germany 
Paraformaldehyde Aldrich, Germany
Peroxidase substrate kit     Vector Laboratories, USA
Rabbit IgG from serum powder  Paraformaldehyde 
Rat VEGF165                                              R&D Systems
Sucrose Sigma, Germany
Super Frost Plus glass slides                           Menzel, Germany 
Tissue-Tek Diatec Sakura Finetek, Europe B.V.
Triton-X100 Sigma, Germany
 25
III.1.5. Polymerase chain reaction       
Gene Ruler 100bp DNA Ladder Fermentas MBI
100bp Leiter Plus PeqLab
NuSieve Agarose Biozym
Random Primer   Roche
Superscript II  Invitrogen
III.1.6. Antibodies for Western blotting
Primary antibodies: dilution Source
rbt pcl α human PEDF                   0.07 µg/ml        BioProducs Maryland, USA
gt pcl α ms PEDF                          0.025 µg/ml           R&D Systems
rb pcl α VEGF A20                         0.6 µg/ml             Santa Cruz, USA 
mcl ms α - b-actin                             1.5 µg/ml                                 Sigma, Germany
Secondary antibodies:
preads. gt α-rb IgG peroxidase                        1:300 BioScource-International 
preads. dk α-gt IgG peroxidase             1:300 Jackson ImmunoResearch 
preads. dk α-ms IgG peroxidase             1:300 Jackson ImmunoResearch 
III.1.7. Antibodies for Immunohistochemistry
Primary antibodies: dilution Source
rbt pcl α PEDF                             20 µg/ml BioProducs Maryland, USA
rbt pcl α VEGF A20                       20 µg/ml Santa Cruz, USA 
gt pcl α Glut-1 C20 (Glucose         1:200 Santa Cruz, USA
transporter 1)                 
ms mcl  α GFAP (Glial acidic       1:600     DAKO, Denmark
fibrillary protein)   
ms mcl α MBP (Myelin basic protein)                          1:400 Chemicon, USA
ms mcl α NeuN (Neuronal Nuclei)                           1:400 Chemicon, USA
ms mcl α ED1 (Ectodysplasin A)                                1:300 Serotec
ms mcl α Ox 42 (macrophage                      1:50 Serotec
complement receptor-3)     
gt pcl α vWF (von Willebrand Factor)                                                            1:200 Santa Cruz, USA  
sh pcl α vWF (von Willebrand Factor)                                                            1:100 Serotec
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Secondary antibodies:
dk-anti-gt IgG- Fluorescein (FITC)     1:400                    Dianova
dk α rbt Rhodamine Red (RHOX)         1:400                    Dianova
dk α gt Rhodamine Red (RHOX)     1:300                    Dianova
dk-anti-ms IgG- Fluorescein (FITC)     1:200                    Dianova
dk-anti-ms IgG-Rhox     1:100                    Dianova
dk anti sh  IgG Fluorescein (FITC)     1:350                    Dianova
dk-anti-rbt-IgG(HL)Biotin-SP     1:300                    Jackson ImmunoResearch 
III.1.8. Solutions
Differentiation medium for RPE Neurobasal medium, 1% FCS, B27 
culture (50x), Pen/Strep, glutamin; 
Digestion medium for cerebllear Hiberante A, 2% (w/v) papain, 1% (w/v)
granule cells DNase 
Growth medium for cerebellar DMEM/F12 medium, 0.2 M KCl, 0.2 M 
granule culture glutamin, Pen/Strep, 1% dFCS, N2
supplement;
Growth medium for RPE culture Neurobasal medium, 20 ng/ml FGF, 
20 ng/ml EGF, 20 ng/ml Heparin, B27 
(50x), Pen/Strep, glutamin 
Paraformaldehyde (4%) dissolve 40 g paraformaldehyd in 800 ml
H2Odist at 60oC while stirring and add 
10 N NaOH until solution is clear; add 
100 ml 10x PBS and fill up to 1 l with
 H2Odist; filter solution
PBS dissolve 2 g KCl, 2 g KH2PO4, 80 g NaCl,
14.4 g Na2HP04x2H2O in 800 ml H2Odist
 
and adjust to 1 l; filter
Phosphatbuffer 154.8 ml 0.5 M Na2HPO4  and 45.2 ml 
0.5 M NaH2PO4   fill up to 1 l with H2Odist
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PPD digestion solution for RPE 2 g/100 ml papain, 100 mg/100 ml 
culture dispase II, 10 mg/ml Dnase I, 12.4 mM 
MgSO4 in Hanks balanced salt solution 
without Mg/Ca;
PVA-DABCO mix 12 g glycerol with 4.8 g polyvinylalco-
 hol over night at room temperature; add 
24 ml Tris pH8, heat for 30 minutes at 
50oC;  DABCO; add 2.5 w/v DABCO, mix; 
centrifuge at 3000 g for 15 minutes; 
store at -20oC;
RIPA buffer 0.1 M PBS, pH 7.4, 1% nonidet p40,
0.1% SDS, 0.5% sodium deoxycholate; 
SDS Sample buffer 2 ml 0.625 M Tris/HCl pH 6.8, 0.2 g SDS,
5 ml glycerol, 0.5 ml β-mercaptoethanol, 
0.1 ml bromophenol blue (1% in ethanol), 
2.4 ml H2Odist;
Sucrose solution dissolve 150 g sucrose in 400 ml 0.1 M
PO4 and adjust to 500 ml with H2Odist; 
filter;
Western blocking solution 0.1 M PBS, pH 7.4, 0.1% Tween 20. 5% 
dry skim milk;
Western washing solution 0.1% Tween in PBS 
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III.1.9. Equipment and Instruments
Adobe Photoshop software, version 7.0 Adobe Systems, USA
AnalySIS software Soft Imaging System GmbH, 
Muenster, Germany 
Cell incubator Heraeus, Germany
Culture hood Cytair, Labortechnik Dunn, Germany       
HP Precision Scan software 3.03 Adobe Systems, USA
ULT Freezor Thermo Forma, Germany
Maxigel chamber  Biometra, Germany 
Olympus BX51 microscope Olympus, Germany
Photodocumentation for Ethidium LTF, Labortechnik, Germany
bromide gels







Experiments in this study were performed in accordance with the German 
guidelines for the use of experimental animals. Wistar and Long Evans rats were 
originally purchased from Charles River (Sulzfeld, Germany) and then bred in the 
animal facility of the University Clinic of Regensburg. Animals were housed under 
normal ambient light conditions on a 12-hour light-dark cycle and had free access 
to food and water. Rats were mated over night and the following day was taken 
as embryonic day (E) 0. Postnatal day (P) 0 was taken as the first 24 hours after 
birth. Animals were sacrificed with intraperitoneal injections of an overdose of 




III.2.2. Western Blot analysis 
To measure the PEDF and VEGF content of complete eyes, male Long 
Evans and Wistar rats were sacrificed at the following ages and n homogenates 
produced: P0 (7n Long Evans, 6n Wistar), 2 weeks (8n Long Evans, 10n Wistar) 
and 1 month (9n Long Evans, 10n Wistar), 2 months (9n Long Evans, 9n Wistar), 
3 months (8n Long Evans, 9n Wistar), 8 months (9n Long Evans, 9n Wistar), 15-
16 months (6n Long Evans, 4n Wistar)  and 20-22 months (3n Long Evans, 3n 
Wistar). Complete eyes were rapidly enucleated, cleaned of surrounding tissue 
on an ice block, frozen in a mixture of dry ice and 2-methylbutane and stored at   
-80oC until further processing. At the same time, complete brains were removed, 
shortly rinsed in PBS and frozen in the same way as eyes. The following number 
of brain homogenates were produced: embryonic day (E)15 (12n Long Evans, 
11n W), E18.5 (8n Long Evans, 10n Wistar), P0 (7n Long Evans, 7n Wistar), P14 
(5n Long Evans, 8n Wistar), 1 month (5n Long Evans, 5n Wistar), 2 months (5n 
Long Evans, 5n Wistar), 3 months (6n Long Evans, 5n Wistar), 7-8 months (8n 
Long Evans, 5n Wistar), 4n 15-22 months Long Evans and 2n 16-24 months 
Wistar. To receive serum, blood was collected from 34 Long Evans animals and 
sedimented for 20 minutes at 13000 rcf after coagulation.  
Frozen eyes and brains were weight, minced with a razorblade in the 
presence of the appropriate amounts of ice-cold RIPA buffer (3 ml/g tissue) that 
was supplemented with protease inhibitors, homogenized with a manual pestle 
and triturated several times with a 20 or 23 gauge needle attached to a 2 ml 
syringe. Tissue homogenates were centrifuged at 10000 g for 20 minutes at 4oC 
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and supernatants were removed and resedimented for an additional 20 minutes 
to yield solubilized extracts. Protein concentrations were determined with a Bio-
Rad DC protein assay and homogenates stored in small aliquots at -80oC to 
avoid repeated freeze-thaw cycles.  
 
To test the protein content of different compartments in the eye, male or 
female Long Evans and Wistar rats were sacrificed at 6 weeks (4 animals per 
homogenate) and 18-19 months (2 animals per homogenate). Their eyes were 
quickly dissected on an ice block and the tissue pooled for homogenization. Eyes 
were cleaned of surrounding tissue and rinsed in RIPA buffer with protease 
inhibitors. After removal of the lens and any remaining aqueous liquor, the 
eyecup was placed into a new dish and the viscous vitreous was pulled off the 
retina with curved fine forceps and the retina was collected. The remaining RPE 
cell layer was collected together with the choroid. Protein homogenates of 
tissues were performed in triplicate as described above. 
 
Changes in protein expression patterns were analyzed by Western 
blotting. Fifty µg of each sample were reduced in an SDS-Sample buffer 
containing 14.4 mM mercaptoethanol, resolved on a 1mm thick 10% SDS 
polyacrylamide gel in a cooled Maxigel chamber and then transferred onto a 
nitrocellulose membrane. To test for equal loading and transfer of samples onto 
the membrane, the membrane was shortly stained with 0.1% Ponceau S and 
scanned into the computer (HP Precision Scan software 3.03). To block 
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nonspecific binding, membranes were placed for one hour at room temperature 
in blocking solution. Blots were incubated in blocking solution over night at 4oC 
with antibodies against purified human or mouse PEDF or a peptide mapping to 
the amino terminal of human VEGF (Santa Cruz, USA). Membranes were 
washed in 0.1% Tween-PBS three times for 15 minutes and incubated with the 
appropriate preadsorbed peroxidase linked secondary antibody for one hour at 
room temperature and washed three times for 15 minutes. Blots were activated 
with a chemo luminescent ECL detection reagent and exposed several times to 
Hyperfilm. As a positive control, and to calculate the PEDF and VEGF content, at 
least three different concentrations of human recombinant PEDF or rat VEGF165 
between 2.5 and 60 ng were loaded on each gel. The same membranes were 
stripped and reblotted with a mcl ms α-β-actin antibody. As a negative control, 
primary antibodies were omitted and films were exposed for equivalent times as 
with specific antibodies, which showed no signal (not shown). The signal strength 
of PEDF and VEGF protein was calculated by digitizing the signals and analyzing 
their density using a NIH image 1.63 software system. Signals were then 
normalized to the ones of β-actin. Since homogenates of whole eyes were used, 
the strength of the actin signal decreased with increasing age of the animal due 
to an increasing ratio of liquid filled compartments in the retina (see Fig. IV.1.1 
and Fig. IV.2.1). Therefore, the actin signal of the two strains was averaged at 
each developmental age and the PEDF signal normalized to the actin content of 
the respective age. Brain signals were normalized to the average β-actin signal 
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of all ages. To determine the amount of PEDF and VEGF in homogenates, 
values were compared to their correspondent standard curve.  
 
III.2.3. Enzymatic digestion of proteins with N-Glycosidase F                                        
For deglycosilation of proteins, a mixture of 50 µg of protein homogenate 
and 0.1% SDS was heated to 100oC for 5 minutes to denature proteins. Trition X 
was added to a final concentration of 0.75%, as well as 4 units of N-Glycosidase 
F and the reaction micture was incubated over night at 37oC in a water bath. 
After addition of  the appropriate amount of loading buffer, the proteins were 
denatured again at 100oC for 3 minutes before loading onto the gel. Western 
blots were processed as described above.  
 
III.2.4. Enzymatic digestion of proteins with Sialidase                                         
For desialylation of proteins, a mixture of 50 µg of homogenate and 500 
mM Sodium phosphate solution of pH 6.0 was prepared and 0.25 units of 
Sialidase added. The reaction mixture was incubated over night at 37oC in a 
water bath and stopped by heating the samples for 5 minutes at 100oC. Western 
blots were processed as described above.  
 
III.2.5. Retinal pigment epithelial cell cultures 
Retinal pigment epithelial cultures were performed as previously described 
by Engelhardt and colleges (2005).  Six 5-week old Long Evans rats were 
sacrificed.  Eyes were enucleated, cleaned and placed in sterile PBS. The RPE 
layer was collected in PBS and centrifuged at 188 rcf at 4oC for 10 minutes. The 
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tissue was then minced with a scalpel in the presence of a few drops of PPD 
digestion solution and further incubated in 5 ml of digestion solution for about 30-
45 minutes at room temperature and triturated every 10 minutes. The digested 
tissue was centrifuged for 10 minutes at 188 rcf at 4 oC, triturated and washed 
two to three times in cold Neurobasal medium containing B27 supplement, 
Penicillin/Streptomycin and 2 mM glutamine until the tissue was broken down. 
Cells were taken up in 2-4 ml of growth medium without serum and placed in a 
plastic dish and incubated at 37oC for 2 days. After 2 days spheres formed which 
were collected, centrifuged and taken up in twice the amount of growth medium 
and plated onto collagen type I (50 µg/ml) coated plastic dishes. Collagen caused 
the spheres to attach and grow out. Cultures were fed twice a week by 
performing a 50% medium change. For passaging of cells, 200 µl of accutase 
was added to the plate and incubated for several minutes at 37oC until cells 
detached from the substrate. The collected cells were then centrifuged, washed 
with Neurobasal/B27 medium and plated in twice the amount of growth medium. 
Differentiation of the cells was achieved by removal of growth factors and 
addition of 1% FCS.  
Differentiated and undifferentiated cell cultures were used for 
homogenization at passage 5. For that purpose, cultures were rinsed once with 
cold PBS, a small amount of RIPA buffer with protease inhibitors added for 
perforation of the membranes, and titurated with a yellow pipette tip. Cell lysates 
were centrifuged once at 10000 g for 20 minutes at 4oC and supernatants 
removed. Protein concentrations were determined with a Bio-Rad DC protein 
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assay and cell lysates and conditioned media stored -80oC in order to test their 
PEDF content by Western blot analysis. For immunohistochemical stainings, 
cells of passage 5 were plated onto glass cover slips that were coated with 
polyornithin (100 µg/ml) and laminin (5 µg/ml) and fixed for 10 minutes with 4% 
PFA. 
 
III.2.6. Cerebellar granule cell cultures 
Four male 7-day old Wistar rats were decapitated. The cerebellum was 
removed under sterile conditions and meninges and large blood vessels removed 
in a medium of Hibernate A and B27. The obtained tissue was minced in small 
pieces, transferred into a digestion medium and agitated at 30oC for about 30 
minutes. After settling of the tissue, the supernatant was discarded and the tissue 
triturated in Hibernate A and B27. Cells were centrifuged at 282 rcf for 10 min at  
4oC, taken up in growth medium and plated on polyornithine covered plastic 
dishes. For immunohistochemical staining, cells were plated on glass cover slips 
that were coated with polyornithine and laminine. Cells were fed every three days 
by performing a partial medium exchange. After 5 days in culture, cells were 
rinsed with PBS and used for homogenization and their conditioned media saved 






III.2.7. Fibroblast cell culture  
Fibroblast cultures were a kind gift of Lars Dreesman, Neurology, 
Naturwissenschaftliches und Medizinisches Institut Reutlingen. In short, ten small 
sections of skin from the back of neonatal green fluorescing CD rats were placed 
on the surface of plastic culture dishes for 10 minutes at 37oC to allow skin 
fibroblasts to adhere to the dish. Cells were cultured in high glucose-DMEM 
medium containing 10% fetal bovine serum (FBS), penicillin/streptomycine, L-
glutamine for 7 to 10 days at 37oC and passaged by digestion with 0.1% trypsin 
and 0.02% ethylendiamine tetraacetic acid in PBS. For immunohistochemical 
staining, cells of passage 6 were plated on laminine coated glass cover slips for 
2 days and fixed for 10 minutes with 4% PFA. For homogenization, cells of 
passage 6 were cultured for 2 days without FBS, and dissolved in Ripa buffer 
containing protease inhibitors, centrifuged for 20 minutes at 10000 g at 4oC and 
stored at -80oC.  
 
III.2.8. Hepatocyte cell culture 
Human hepatocytes were a kind gift of Dr. Thomas Weiss, Department of 
Surgery, University Clinic of Regensburg. Primary hepatocytes were isolated 
from adult human liver and cultured as described by Weiss and colleges (2003). 
In short, hepatocytes were cultured on collagen in DMEM medium containing 100 
mU penicillin, 100 µg/ml streptomycin, 10 ng/ml glucagon, 125 mU/ml insulin and 
60 ng/ml hydrocortisone without serum. For experimental use, cells were cultured 
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for 2 days, their conditioned media saved for PEDF analysis and cells were 
prepared for homogenization as described above.  
 
III.2.9. Immunohistochemistry 
 For immunohistochemical stainings of eyes, tissues were prepared as 
following: deeply anesthetized animals were first perfused intracardially with 
0.9% NaCl, and then with fresh 4% PFA. Eyes were enucleated, placed in 4% 
PFA over night at 4oC and then equilibrated in a 30% sucrose solution until the 
next day. Eyes were cleaned of surrounding tissue and part of the cornea and 
the lens were removed. The remaining eye cup was embedded in Tissue-Tek 
and frozen in a mixture of 2-methylbutane and dry ice. Several eyes of the same 
age from both strains or one eye of each developmental age of both strains were 
frozen in the same Tissue-Tek block. Cryosections of 8 µm were collected on 
Super Frost Plus glass slides and neighboring slices were stained to detect 
PEDF and VEGF protein. In total 5x P0, 5-6x P14, 3x 3 month and 3x 15-17 
month old Wistar and Long Evans rat eyes were stained and analyzed. 
 For immunohistochemical studies of brains, the brains of deeply 
anesthetized male Long Evans were removed and frozen in a mixture of dry ice 
and 2-methylbutane and placed in Tissue-Tek. In total, brains from 7x P0, 5x P7, 
6x P14, 6x P28, 6x 3 months and 7x 15-17 months old male Long Evans animals 
were processed. Brain cryosections of 7 µm were collected on Super Frost Plus 
glass slides, dried for 2 hours and fixed with fresh 4% PFA up to 2 hours. After 
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washing with 0.1% Triton X 100 in PBS cryosections were stained on the same 
day to detect PEDF protein. 
 All eye and brain sections were first incubated in 3% milk and 0.1% 
Triton X-100 in PBS for 60 minutes at room temperature to block nonspecific 
binding. Each specific antibody was diluted in blocking solution and incubated 
overnight at 4oC in a humidified chamber. Slides were washed three times for 15 
minutes with PBS plus 0.1% Triton X-100. For DAB stainings, endogenous 
peroxidase activity was blocked for 30 minutes in 0.3% hydrogen peroxide in 
washing solution. Sections were then incubated with peroxidase labeled 
secondary antibody for at least two hours at room temperature in a humidified 
chamber, washed three times, incubated for 1-2 hours with an avidin-biotin 
complex and developed with a commercially available DAB peroxidase substrate 
kit. Slides were mounted using Neo-Mount mounting medium.  
 For double labeling, fluorescent staining was performed. Blocking and 
washing solutions were the same as described above. While eyes were 
incubated over night at 4oC in the dark with a combination of employed primary 
antibodies, brains were first stained for rbt pcl α-PEDF on the first day and on the 
second day with the other primary antibody of choice in 1% BSA. After incubation 
of each primary antibody, slices were washed 3 times and incubated with the 
appropriate fluorescing secondary antibody. Cryosections were washed and 
mounted with PVA-DABCO. 
 Control slides were performed in parallel with actual stainings and were 
either treated as following: omitting the primary antibody, substituting the primary 
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antibody with preimmune IgGs at the same concentration of the corresponding 
primary antibody and preadsorption of the anti-PEDF antibody with an excess of 
PEDF of 100 times its molarity at 4oC over night and centrifugation for 30 minutes 
at 20000 g. Tissues were analyzed with transmitted light (bright field) or 
fluorescent light using an Olympus BX51 microscope. Images were taken directly 
from the microscope to a computer image system (analySIS). Similar areas of 
the eye of both rat strains were used for stainings as well as pictures. Processing 
of images of stainings and their controls was performed in parallel and was 
performed using Adobe Photoshop software which included adjustment of 
brightness and contrast to achieve similar background levels and scaling to final 
size.  
 
III.2.10. Measurement of retinal ganglion cell staining intensity 
For measurement of retinal ganglion cell (RGC) staining intensity, eyes of 
3 different Long Evans and Wistar animals at P0, P14, 3 months and 15-17 
months were stained in parallel for PEDF using DAB. Images of RGC’s were 
taken with the same camera and light settings and the staining intensity of 20 
RGC’s per animal was measured using the software ImageJ 1.33U. Obtained 
values were adjusted for background absorption outside the stained retina. For 





III.2.11. Statistical Analysis 
All results are expressed as the mean ± standard error of the mean 
(SEM). To determine if age had a significant effect on the PEDF or VEGF content 
of eyes, brains, serum or the staining intensity or RGC’s, first a Kruskal-Wallis 
test was performed. If the Kruskal-Wallis test showed a significant effect of age, 
then a Mann-Whitney-U test was used to test if there were differences in the 
expression of PEDF and VEGF between Wistar and Long Evans strains at each 
postnatal age. A Spearman rank correlation test was employed to determine the 
changes in PEDF and VEGF protein expression over time. Differences were 
considered statistically significant when P< 0.05.  
 
III.2.12. Polymerase chain reaction (PCR) 
cDNA from various human blood cells was a kind gift of Dr. Michael Rehli 
and Dr. Sven Heinz, Department of Hematology, University Clinic of Regensburg. 
For PCR of the PEDF gene a Taq PCR Master Mix was employed. The following 
primers were used for the detection of human PEDF mRNA: 5’-tat gac ttg atc agc 
agc cc-3’ (forward) and 5’-agc ttc atc tcc tgc agg ga -3’ (reward) which yield a 
663 bp long product, and of GAPDH mRNA: 5’- ggt cgg tgt gaa cgg att tg -3’ 
(forward) and 5’-ggt cgg tgt gaa cgg att tg-3’ (reward) which yield a 318 bp long 
product. PCR amplifications were performed for 30 cycles. Each cycle included 
denaturation at 94oC for 45 seconds, annealing of primers at 61oC and extension 
of primers at 72oC for each 1 minute. PCR products were separated on a 1.5% 
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agarose gel which contained 0.5% ethidium bromide and specific DNA bands 
were examined under an ultraviolet transilluminator. 
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IV. PEDF protein content and localization in the eye and its comparison to 
VEGF. 
 
IV.1. Is there a difference in the PEDF content or protein location between 




In the eye, PEDF has been detected in several cell types of various 
species (Becerra et al., 2004; Behling et al., 2002, Karakousis et al., 2001; Ogata 
et al., 2002, Ortego et al., 1996; Wu et al., 1995) and exists in basically all 
compartments of the eye, including the vitreous, RPE, retina, choroid, ciliary 
body, lens and cornea. In the vitreous of several speices, PEDF has been 
estimated to be between 1-2 µg/ml or 20-40 nM and is about 10-fold lower than 
in the interphotoreceptor matrix (Barnstable and Tombran-Tink, 2004). Within the 
retina, RPE cells secrete PEDF into the interphotoreceptor matrix and are the 
main source of PEDF production.  
In addition to its neuroprotective effects on photoreceptor cells (Cao et al., 
2001; Cayouette et al., 1999; Jablonski et al., 2000) and retinal neurons (Cao et 
al., 1999; Ogata et al., 2001a), it has been shown that PEDF supports normal 
Mueller glia development (Jablonski et al., 2001), induces the morphogenesis of 
photoreceptor neurons of Xenopus laevis (Jablonski et al., 2000), as well as the 
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differentiation and maturation of pigment granules of albino RPE cells from 
Wistar rats in retinal cultures (Malchiodi-Albedi et al., 1998).  
Albinism is generally heterogeneous but manifests the same 
abnormalities, which include an underdevelopment of the central retina, 
abnormal chiasmatic routing of temporal retinal axons, reduction of about 30% of 
rod photoreceptor numbers and the lack of mature melanosomes. It has been 
shown that there is a relation between the melanin content and rod numbers, 
ocular rhodopsin, as well as the degree of misrouting at the chiasm (Donatien 
and Jeffery, 2002) indicating the importance of melanin in the eye. 
 Since there are indications that PEDF plays a role in the differentiation 
and maturation of pigment granules, it could be therefore hypothesized that lower 
levels of PEDF might be related to the albino phenotype in comparison to 
normally pigmented eyes. In order to test this hypothesis, the PEDF content and 
localization were compared in pigmented Long Evans and albino Wistar rats. For 
this purpose, homogenates of complete rat eyes and retinas were prepared from 
birth until adulthood and their PEDF content measured by Western blot analysis. 
Retinas from both rat strains were immunohistochemically stained for PEDF to 




Whole eye homogenates from male Long Evans and Wistar rats of various 
postnatal ages were separated by Western blot analysis. As a positive control 
and to calculate the PEDF content in the eye various concentrations of human 
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recombinant PEDF were used. The purified PEDF protein migrated at the same 
molecular weight as the protein found in the eye samples and was detected 
slightly below 50 kDa (Fig. IV.1.1b). Omitting the primary antibody showed no 
staining (data not shown) and both anti-PEDF antibodies gave the same results 
(data not shown), indicating the specificity of the primary antibodies. 
At birth, PEDF levels were high and Long Evans eyes had virtually the 
same amount of PEDF as Wistar eyes and contained 1.27±0.06 and 1.28±0.02 
ng/µg protein, respectively (Fig. IV.1.1a). Although at P28 and 3 months there 
was a maximum decrease of PEDF of 22% compared to levels at P0, the PEDF 
content remained high during the first three months of age. There was no 
significant difference between the two rat stains at any of the ages tested and in 
total, Wistar rat eyes contained 1.8 % less PEDF compared to Long Evans eyes.  
A Spearman rank correlation showed no significant effect of age on the overall 
PEDF content in the eye for both Long Evans (n=41, r=0.057, P=0.72) and 
Wistar rats (n=43, r=-0.2, P=0.2).  Overall, Western data indicate that there was 
no significant difference in the PEDF content of complete eyes between the two 
strains (P=0,847, n=84). 
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Fig IV.1.1. PEDF content of complete Long Evans and Wistar rat eyes from birth 
until 3 months of age.  
A) 50 µg of complete eye homogenates of animals between PO and 3 
months were analyzed by Western blot analysis. PEDF was normalized to 
the average actin signal at each age and then compared to a standard 
curve of PEDF (20-50 ng, not shown). Data are shown as mean ± SEM.  
Black bars represent eyes of Long Evans rats and white bars Wistar eyes. 
A Mann-Whitney-U test showed that overall there was no significant 
difference between the two rat strains (P=0.847, n=84). Although there 
was a significant difference in the PEDF content in eyes between P0 and 
P14 (P=0.006, n=40) and between 1 and 2 months (P=0.031, n=37), a 
Spearman Ranks test showed that overall age had no significant effect on 
the PEDF content in either strain (Long Evans: n=26, r=-0.845, P<0.000; 
Wistar: n=24, r=-0.737, P<0.000). 
B) Underneath the graph a Western Blot of one representative sample per 
age is shown for PEDF and actin. PEDF samples comigrated with the 
positive control (lane 1, 50 ng) and were detected slightly below 50 kDa. 
 
To examine if there are differences between the two rat strains in the 
PEDF protein localization within the retina that could be correlated with the albino 
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phenotype of Wistar rats, retinas were immunohistochemically stained for PEDF 
at P0, P14 and 3 months of age (Fig. IV.1.2). Stained slices were compared to 
the appropriate IgG controls, which were negative in all cases (Fig. IV.1.2H). 
Preadsorption of the PEDF antibody also showed no staining (Fig. IV.1.2G), 







Fig. IV.1.2) DAB immunocytochemical localization of PEDF in Long Evans (left 
panel) and Wistar (right panel) retinas at PO (A, B), P14, (B, C) and 3 months (E, 
F). Picture (G) shows a preadsorption control and (H) an IgG control of the 3 
month old Long Evans retina. Note the strong staining of vessels on the surface 
of the retina (arrows), as well as the clear reaction of RGC somata for PEDF in 
both strains. Abbreviations: CC, choroid; INL inner nuclear layer; INS, inner 
synaptic layer; ONL, outer nuclear layer; OSL, outer synaptic layer; NBCL, 
neuroblastic cell layer; PhR, photoreceptors; RGC, retinal ganglion cells; RPE 




Prominent staining for PEDF was seen in retinal ganglion cells (RGC) at all 
ages in both rat strains. To test if a difference in staining intensity might indicate 
a difference in PEDF content, the RGC staining intensity was measured.  
Measurements indicated that the staining intensity increased with increasing age 
and was the highest at 3 months of age (Fig. IV.1.3). There was a significant 
increase in the staining intensity of RGC’s between P0 and P14 (P=0.002, n=12), 
but not between P14 and 3 months of age (P=0.132, n=12). Although the RGC 
staining intensity between Long Evans and Wistar eyes could not be statistically 
compared at each age, it appeared as if RGC’s of both strains stained to similar 





Fig IV.1.3) RGC staining intensity of PEDF of retinas between birth and 3 
months.  
PEDF DAB staining of retinas from three different Long Evans (black bars) and 
Wistar (white bars) animals was performed in parallel and the staining intensity of 
20 RGC’s from each animal was measured and adjusted to the background. A 
Kruskall Wallis test for Long Evans and Wistar RGC’s combined (gray bars) 
showed a significant overall effect of age on RGC staining intensity (P=0.002, 
n=18). When ages were compared among each other, a Mann-Whitney-U test 
showed that there was a significant difference in the RGC staining intensity 
between P0 and P14 (P=0.002, n=12), but not between P14 and 3 months of age 
(P=0.132, n=12). Significant changes between ages are indicated by asterisks. 
 
Overall, there was no obvious difference in the location of the PEDF signal 
between rat strains. At each age tested, the different retinal layers seemed to 
stain to similar degrees in Long Evans and Wistar rats as supported by the 
measurement of the RGC staining intensity. There was an increase in the overall 
staining intensity after birth, but retinas at two weeks stained to similar degrees 
as at three months. Since overall there were no obvious differences in the 
staining location between the two rat strains and the staining intensities appeared 
similar as well, the following description of the PEDF staining accounts for both 
rat strains.  
The PEDF staining of the inner nuclear layer (INL) was not as strong as 
for RGC’s, and not all cells in the INL stained for PEDF. Cells in the INL facing 
the RGC layer tended to stain more often than the ones facing the outer nuclear 
layer (ONL). This was already apparent at P0 when the different retinal layers 
had not fully differentiated yet and only cells of the neuroblastic cell layer facing 
the RGC layer stained for PEDF. In general, the ONL stained relatively weak for 
PEDF, but was somewhat stronger stained at 2 weeks of age compared to  
adulthood and only some cells of the ONL showed a rather weak signal for 
 49
PEDF, while others were negative. Photoreceptors weakly stained for PEDF at 2 
weeks, but not at 3 months of age.  
PEDF immunoreactivity of RPE cells was very intense at all ages tested 
and the nuclei of RPE cells heavily stained for PEDF as determined by nuclear 
staining (see also Fig. IV.2.4). In the Wistar rat, the staining intensity of the 
choroid was fairly strong between birth and adulthood. Due to the pigmentation it 
was difficult to determine if the immunoreactivity of the choroid of Long Evans 
rats was comparable to that of Wistar rats. The sclera also showed fairly 
prominent staining for PEDF at all ages. A strong PEDF staining of blood vessels 
was observed in both strains at all ages, which was however especially strong at 
birth, when the antibody labeled the nuclei and cytoplasm of endothelial cells on 
the surface of the retina. 
To verify that Long Evans and Wistar retinas in fact contained similar 
amounts of PEDF as indicated by immunohistochemical stainings, and to 
examine the PEDF content of the retina in more detail, homogenates were 
prepared from retinas of 6 weeks old rats (Fig. IV.1.4). Preliminary Western blot 
results showed that young Long Evans and Wistar retinas appeared to contain 
similar amounts of PEDF, although there was a tendency for Wistar retinas to 
contain slightly less PEDF.  
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Fig. IV.1.4) PEDF content of retinas of 6 weeks old Long Evans and Wistar rats. 
50 µg of three homogenates of retinas of 6 weeks old Long Evans (LE) and of 
Wistar (W) rats were analyzed by Western blot analysis. PEDF signals were 
normalized to the average actin. Data are shown as mean ± SEM.   
 
Discussion:  
Western results showed that the PEDF content in the entire eye was not 
significantly different in both rat strains from birth until young adulthood and did 
not significantly change with age, indicating that the PEDF content of entire eyes 
does not differ between albino and pigmented eyes and thus might not be related 
to the albino phenotype.  
However, PEDF can accumulate to different degrees in different 
compartments of the eye, and the retina is not the primary source of PEDF within 
the eye.  To determine if more subtle differences in PEDF distribution or 
production might be related to the albino phenotype, special attention was put on 
the retina that also contains melanosomes. The immunohistochemical staining of 
retinas for PEDF of this study are in good agreement with another study that 
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investigated the location of PEDF in the mouse retina between embryonic day 
14.5 and 3 month old animals (Behling et al., 2002). Rat strains were similar in 
respect to the specific PEDF protein location and expression, as indicated by 
measurement of the RGC staining intensity, furthermore indicating that the PEDF 
protein might not be related to the albino phenotype. The finding that the PEDF 
content of 6 week old retinas appeared to be similar furthermore indicates that 
the two rat strains did not differ in the PEDF content and localization of the retina.  
 Interestingly, the overall PEDF staining signal was the weakest at birth, 
although the PEDF content of the entire eye was the highest at this age. Since 
previous reports show that the PEDF content in the retina is relatively low 
compared to other compartments in the eye, the immunohistochemical staining 
intensity of the retina may therefore not be a good indicator for the PEDF content 
of the entire eye. One explanation that might explain the apparent discrepancy 
between the PEDF content of complete eyes and the immunohistochemical 
staining intensity at birth is that the antibody appeared to label only the already 
differentiated RGC and RPE layer, while the undifferentiated neuroblastic cell 
layer was for the most part negative for PEDF. This is supported by previous 
reports that show that in vitro undifferentiated RPE cells do not produce PEDF 
contrary to differentiated cells (Ohno-Matsui et al., 2001). This is insofar 
interesting, since PEDF is upregulated in young, quiescent cells of the G0 state, 
and low in replicating cells, so that it is thought that PEDF might have an 
inhibitory effect on the cell cycle (Pignolo et al., 1993 and 2003). A lack of PEDF 
in undifferentiated replicating cells would also be in line with reports that have 
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shown that PEDF induces the differentiation of various cell types including RPE 
cells, Muller glia and photoreceptors. Thus, a low immunohistochemical PEDF 
signal of the retina at birth may not be contradictory to a high PEDF content of 
the entire eye. 
 
 Presently, it is not known whether PEDF might have some kind of function 
in the cell before its secretion into the extracellular space. The fact, that PEDF is 
produced by RPE cells (Tombran-Tink et al., 1995), binds to them (Aymerich et 
al., 2001) and has been shown to induce their pigmentation in culture (Malchiodi-
Albedi et al., 1998), indicates that an autocrine mechanism and therefore also its 
secretion might be important for its function. This is also supported by the finding 
that nuclei of endothelial, RPE cells and potentially also RGC’s stained for PEDF, 
which suggests that the protein may be taken up by the cell and function as a 
signaling molecule in the cell body, as is the case for nerve growth factor 
(Delcroix et al., 2004). In fact, it has been shown that PEDF is taken up by 
injured motor neurons, transported retrogradely and reduces their cell death 
(Houenou et al., 1999), also suggesting that PEDF may function as a signaling 
molecule in the nucleus.  
Taken together, the data of this study indicate that there were no 
differences in between rat strains from birth until young adulthood in the PEDF 
protein content of entire eyes, and probably also not of the retina, as well as in 
the PEDF location within the retina, which supports the idea that PEDF might not 
be related to the lack of pigmentation in albino Wistar eyes.  
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It is not clear why in complete retinal cultures PEDF was able to induce 
pigmentation of RPE cells of neonatal Wistar eyes (Malchiodi-Albedi et al., 1998), 
although the present study indicates that pigmented Long Evans and albino 
Wistar eyes do not differ in the PEDF content and localization. Further studies 
would be necessary to clarify if there might be differences in between strains 
regarding the PEDF content of the retina and of the RPE layer especially during 
embryogenesis and at younger ages than 6 weeks. It would be also important to 
know if differences in the amount and location of the PEDF receptor might exist 
in the RPE layer and if cell culture conditions might possibly induce the 
expression of the PEDF receptor or of yet another factor in the reaction cascade 
of PEDF, thereby inducing the pigmentation of RPE cells. 
It would be furthermore interesting to find out if there are differences in the 
posttranslational processing of PEDF in the retina between the two rat strains, 
since it has been shown that differences in posttranslational processing can 
change the function of PEDF (Maik-Rachline et al., 2004). It also has been 
reported that there are differences in the posttranslational processing of PEDF 
depending on where the protein is produced in the eye. For instance, the N-
terminal of PEDF from the bovine interphotoreceptor matrix has been found to be 
unblocked (Wu et al., 1995), but is blocked in bovine vitreous and in human 
blood (Wu and Becerra, 1996; Peterson et al., 2003), indicating that PEDF is 
processed differently in different compartments of the eye. Thus, changes in 
posttranslational processing could possibly explain why certain functional 
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aspects of PEDF might differ in between the two rat strains although they do not 
differ in the PEDF content and location in the eye. 
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IV.2. Is a loss of PEDF protein content or a change in PEDF localization 
related to the degeneration of the Wistar retina at old age? 
 
Introduction: 
Several studies provide evidence for the neuroprotective effect of PEDF 
on various cell types in the eye (Tombran-Tink and Barnstable, 2003b; 
Barnstable and Tombran-Tink, 2004). Pretreatment with PEDF protects rat retinal 
neurons from hydrogen peroxide-induced cell death in culture (Cao et al., 1999), 
transiently delays the death of photoreceptors cells in the rd/rd and rds/rds 
mouse models of retinitis pigmentosa (Cayouette et al., 1999), protects 
photoreceptors from light induced damage (Cao et al., 2001), and has a 
neuroprotective effect on the inner layers and ganglion cells of the retina under 
ischemic conditions (Ogata et al., 2001a).  
It has been shown previously that at old age, the Wistar retina shows 
signs of degeneration including the loss of photoreceptors (Sullivan et al., 2003; 
Weisse, 1995), while the retina of old pigmented Long Evans rats appears 
morphologically intact. In fact, this age-dependent, ambient light-induced 
degeneration of the Wistar rat retina has been shown to be related with AMD in 
humans (Sullivan et al., 2002). Because of its neuroprotective effect in the retina 
against phototoxic and oxidative stress, it could be therefore hypothesized that a 
loss of PEDF might be related to the observed degeneration in old Wistar retinas 
compared to morphologically intact Long Evans retinas.  
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To test this hypothesis, complete eyes of Wistar and Long Evans rats 
between 3 and 24 months of age and retinas from 18-19 month old animals were 
homogenized and their PEDF protein content measured by Western Blot 
analysis. In order to compare the localization of PEDF protein within the retina, 




  As previously shown the PEDF content of complete rat eyes was the 
highest at birth (1.27±0.06-1.28±0.02 ng/µg protein) and remained fairly high until 
3 months of age in both rat strains (Fig. IV.1.1). After 3 months however, PEDF 
decreased and reached its lowest level at the oldest age tested, at which time the 
PEDF content was only about 22.8 - 26.6% from values at birth, or 0.29±0.03 
and 0.34±0.03 ng/µg protein for Long Evans and Wistar rats, respectively (Fig. 
IV.2.1). At 8 (P=0.031, n=18) and 15-16 months of age (P=0.048, n=9), there 
was a significant difference in the amount of PEDF between Long Evans (8 
months: 0.51±0.04 ng/µg and 15-16 months: 0.42±0.05 ng/µg) and Wistar rats (8 
months: 0.72±0.07 ng/µg and 15-16 months: 0.63±0.05 ng/µg). Between 3 and 




                                 
Fig IV.2.1) PEDF content of complete Long Evans and Wistar eyes from 
adulthood until old age.  
A) 50 µg of complete eye homogenates of animals between 3 and 22 months 
were analyzed by Western blot analysis. PEDF was normalized to the 
average actin signal at each age and then compared to a standard curve of 
PEDF (20-50 ng, not shown). Data are shown as mean ± SEM.  Black bars 
represent eyes of Long Evans rats and white bars Wistar eyes. A Mann-
Whitney-U test showed that overall there was no significant difference 
between the two rat strains (P=0.145, n=50), although at 8 (P=0.031, n=18) 
and 15-16 months (P=0.048, n=9) Wistar eyes contained significantly more 
PEDF than Long Evans eyes. A Spearman Ranks test showed that overall 
the PEDF content in both strains significantly decreased with increasing age 
(Long Evans: n=26, r=-0.845, P<0.000;  Wistar: n=24, r=-0.737, P<0.000). 
Significant changes between rat strains are indicated by asterisks. 
B) Underneath the graph a Western Blot of one representative sample per age is 
shown for PEDF and actin. PEDF samples migrated at the same height as 
the positive control (lane 1, 50 ng) and were detected slightly below 50 kDa. 
 
 58
To determine if the overall protein content of the entire eye was reflected 
by the staining pattern in the retina, eyes from 15-16 months old Long Evans and 
Wistar rats were stained immunohistochemically for PEDF. Appropriate IgG and 
preadsorption controls were negative in all cases (Fig. IV.2.2.C and D) indicating 






Fig. IV.2.2) DAB immunocytochemical localization of PEDF in a 15-16 month old 
Long Evans (A) and Wistar (B) retina. Picture (C) shows an IgG control and (D) a 
preadsorption control of the same Wistar retina as shown in (B). The pictures 
show the large lumen of vessels in the choroid and vessels that transverse the 
entire retina (arrows) as well as holes in close vicinity to the RPE layer in the 
Wistar retina (arrow heads). Also note the appearance of some cells in the ISL of 
the Wistar retina as indicated by arrow heads. Abbreviations: CC, choroid; INL 
inner nuclear layer; ISL, inner synaptic layer; ONL, outer nuclear layer; PhR, 
photoreceptors; RGC, retinal ganglion cell layer; RPE retinal pigment epithelial 
cell layer; SCL, sclera;  
 
Figure IV.2.2B shows a typical example of a degenerated Wistar retina at 
old age.  In all Wistar eyes tested, the photoreceptor layer, as well as the outer 
nuclear layer was degenerated nearly completely almost all over the entire eye, 
and remnants could only be found in some areas of the retina. Age-matched 
Long Evans retinas (Fig. IV.2.2A), however, appeared morphologically intact. 
Holes were found in the close vicinity of the RPE layer of old Wistar retinas 
contrary to Long Evans eyes. Furthermore, especially large lumina of blood 
vessels could be observed frequently in the choroid of old Wistar eyes, while the 
choroid of old Long Evans retinas did not appear different from 3 months old 
animals. In some cases blood vessels also transversed the entire Wistar retina, 
which was not observed in old Long Evans retinas.  
In general, the same retinal layers that were labeled for PEDF at younger 
ages also stained in both rat strains at old age, although with lower intensity. 
Measurement of the staining intensity of RGC somata indicated that although the 
staining of RGC’s was still prominent at high age, it was significantly decreased 
compared to 3 month old animals (P=0.015, n=12) (Fig. IV.2.3). Although it was 
not possible to perform a statistical analysis in between rat strains, it appeared 
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that RGC somata of both rat stains stained with similar intensities for PEDF at old 
age (see Fig. IV.2.3 and IV.2.2). In old Long Evans retinas, photoreceptors were 
labeled for PEDF, while the few leftover photoreceptors in Wistar retinas did not 
stain for PEDF (not shown). Fluorescent stainings showed, that in Wistar retinas 
the nuclei of RPE cells stained very faint for PEDF compared to strongly labeled 
nuclei of RPE cells of Long Evans retinas (Fig. IV.2.4). Furthermore, the RPE 
layer of old Wistar rats contained a large amount of auto fluorescent lipofuscin 
which could not be observed in age-matched Long Evans eyes (Fig. IV.2.4).  
 
 
Fig IV.2.3) RGC staining intensity of retinas at 3 and 15-19 months.  
PEDF DAB staining of retinas from three different Long Evans (black bars) and 
three Wistar (white bars) animals was performed in parallel and the staining 
intensity of 20 RGC’s from each animal was measured and adjusted to the 
background. A Kruskall Wallis test for Long Evans and Wistar RGC’s combined 
(gray bars) showed a significant effect of age on the RGC staining intensity 





Fig. IV.2.4) Fluorescent PEDF staining of RPE cells in Long Evans (A) and 
Wistar (B) retinas at old age. Pictures C and D show the corresponding Hoechst 
stainings to indicate the location of RPE nuclei as shown by arrow heads. PEDF 
images of both rat strains were taken with the same camera settings and their 
contrast adjusted in parallel. The figure shows that RPE cells of Long Evans eyes 
stained much stronger than those of Wistar eyes, which contained however a 
large amount of auto fluorescent lipofuscin as indicated by arrows.  
 
 
Interestingly, the choroid of old Wistar retinas was widened and contained 
a large amount of strongly stained cells that had not been observed at younger 
ages (Fig. IV.2.2). At old age, only the nuclei of cells in the sclera were positive 
for PEDF as determined by nuclear staining (data not shown). Furthermore, in 
the Wistar retina somata could also be observed in the ISL, a layer that normally 
does not contain any cell bodies (Fig. IV.2.2).  
Since signs of retinal degeneration usually are accompanied by 
proliferation and migration of microglia, a double labeling of PEDF and the 
microglia/macrophage markers Ox42 and ED1 was performed to test if these 
cells might stain for PEDF. Only a small amount of cells stained for Ox42 and 
ED1 that were mainly located on the surface of the retina (Fig. IV.2.5; data for 





Fig. IV.2.5) Fluorescent double staining of a degenerated Wistar retina at old age 
with PEDF (A) and Ox42 antibody (B). The figure shows that microglia on the 
surface of the retina immunoreacted with both PEDF and Ox42 antibodies which 
is indicated by arrows.  
 
 
In order to determine the PEDF content of the retina at old age, retinal 
homogenates of 18-19 month old Wistar and Long Evans rats were prepared. 
Preliminary data indicate that old Wistar retinas contained about 45% less PEDF 
than age-matched Long Evans retinas (Fig. IV.2.8). In comparison with 6 week 
old animals, old Long Evans retinas even contained slightly more PEDF (about 
10%), while old Wistar retinas showed a decrease of PEDF of 35%. 
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Fig. IV.2.8) PEDF content of retinas of 6 weeks and 18-19 month old Long Evans 
and Wistar rats. 50 µg of three homogenates of different retinas of each Long 
Evans (black bars) and Wistar rats (white bars) were analyzed by Western blot 
analysis. PEDF signals were normalized to the average actin. Data are shown as 
mean ± SEM.   
 
In summary, although in the entire eye PEDF significantly decreased with 
increasing age in both strains, in old animals the same retinal layers stained for 
PEDF as in young adult animals and no obvious difference in staining location 
could be found in between strains. Overall, the staining was reduced compared 
to 3 months old animals as indicated by the measurement of RGC staining 
intensity. Nuclei of RPE cells of old Wistar retinas stained however much less 
compared to Long Evans eyes and retinas of old Wistar rats contained less 
PEDF than of Long Evans rats.  
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Discussion:  
As hypothesized, Western results showed that in entire eyes there was a 
significant downregulation of PEDF with increasing age in both rat strains. This is 
in agreement with a previous study that has shown that PEDF is downregulated 
with increasing age in the aqueous humor of humans (Ogata et al., 2004). PEDF 
has also been shown to be downregulated in senescent cells, such as fibroblasts 
and RPE cells (Pignolo et al., 1993 and 2003; Tombran-Tink et al., 1995). Thus, 
the downregulation of PEDF in the entire old eye appears to be a natural 
phenomenon that might be associated with the decline of the cell cycle rate and 
might not be related to the observed degeneration of old Wistar retinas. 
Contrary as hypothesized, between 8 and 16 months of age Wistar eyes 
contained significantly more PEDF than Long Evans eyes, suggesting that a low 
PEDF content in the entire eye is not associated with the observed degeneration 
of the Wistar retina. Ogata and colleges (2003) have shown that there is a 
significant difference in the PEDF content in the vitreous between men and 
women at old age. Although only male rats were tested, it is possible that the 
difference in PEDF content of Wistar and Long Evans rat eyes between 8 and 16 
months might be genetic and therefore strain specific. Considering its 
neuroprotective effect in the eye, it could be hypothesized that the increased 
content of PEDF in entire Wistar eyes, as well as its still prominent staining in 
degenerated Wistar retinas might be a compensatory mechanism to prevent 
retinal degeneration, although unsuccessfully. In fact, PEDF has been shown to 
be upregulated in the vitreous of rhegmatogenous retinal detachment, where it 
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has been suggested to act as a neuroprotective agent for the detached retina 
(Ogata et al., 2001b). This idea would however not be in agreement with 
preliminary data that suggest that Wistar retinas contain less PEDF than Long 
Evans retinas.  
 
Interestingly, in contrast to younger ages and age-matched Long Evans 
retinas, PEDF-stained cell bodies appeared in the choroid and ISL of old Wistar 
eyes. In fact, migration of neurons, as well as extension of Muller cell processes 
through holes in the Bruch’s membrane into the choroidal region has been shown 
to occur in degenerated retinas of old Wistar rats (Sullivan et al., 2003). Sullivan 
and colleges also showed that the causal agent in this degenerative process was 
light, although albino rats were maintained under normal animal house lightening 
conditions of 750 lux. The appearance of somata within the choroid and the ISL 
therefore suggests a migration of cells within old Wistar retinas. The reason for 
the observed remodeling and migration of cells within the retina is presently 
unknown, but may potentially serve to retard retinal degeneration (Sullivan et al., 
2003).  
 
Similar to Western blot results of entire eyes, some aspects of 
immunohistochemical data of the retina also suggest that PEDF may not be 
related to the degeneration of the retina at old age. First, In general the same 
retinal layers stained for PEDF at old age in both strains compared to younger 
ages. Second, the overall retinal staining remained similarly strong in both 
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strains, although RGC staining intensities were significantly lower at old age 
compared to 3 month old animals, thereby reflecting the overall decrease of 
PEDF with increasing age.  
 
However, other, more subtle changes indicate that a decrease of PEDF 
within the retina could be related with the degeneration of old Wistar retinas. 
First, RPE cells -the main PEDF source in the retina- stained obviously less in 
old Wistar retinas compared to Long Evans retinas as indicated by fluorescent 
stainings, and the remaining photoreceptor cells in old Wistar retinas did not stain 
for PEDF contrary to Long Evans photoreceptors. This would be in line with a 
decreased production of PEDF by RPE cells, since they secrete PEDF into the 
interphotoreceptor matrix (Becerra et al., 2004). In fact, in vitro experiments have 
shown that senescent RPE cells, RPE cells under oxidative stress or irradiated 
with near-ultraviolet light all have a reduced PEDF production (Tombran-Tink et 
al., 1995; Ohno-Matsui et al., 2001; Matsunaga et al., 1999; Li et al., 1999). 
Recently it has been made possible to visualize senescent cells by staining for 
beta galactosidase and it was shown that replicative senescence of RPE cells 
also takes place in old monkey eyes (Hjelmeland et al., 1999), suggesting that in 
vivo PEDF production may be in fact also downregulated in RPE cells at old age.  
Second, another characteristic of senescent RPE cells in vivo is the 
progressive accumulation of auto fluorescent lysosomal material (lipofuscin) 
(Hjelmeland et al., 1999) which was also observed in old Wistar retinas of this 
study. Drusen are the earliest morphological features of AMD in humans and are 
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basal deposits of granular material with widened collagen or vesicles and 
membranous profiles external to the RPE (Green, 1999). The observation that 
holes, or possibly Drusen, were in close contact with the RPE layer, furthermore 
suggest a malfunctioning of the RPE layer which could cause a decrease in 
PEDF production. In support of this idea is the finding of Sullivan and colleges 
(2003) who have shown a degeneration of the RPE layer and Bruch’s membrane 
in old Wistar retinas. 
Third, preliminary data suggest that the degenerated Wistar retina 
contains less PEDF than the morphological intact Long Evans retina whose 
PEDF levels were even slightly increased compared to retinas of young animals. 
Since Wistar eyes do not contain any pigments, that among other things reduce 
the photochemical stress in the retina, the lack of melanin and the increased 
reactive oxygen species could potentially lead to a lower PEDF production within 
the Wistar retina at old age. 
Because PEDF supports the normal development of photoreceptor 
neurons after removal of the RPE (Jablonski et al., 2000), it is therefore likely that 
a decrease in the PEDF production by RPE cells due to pathological changes in 
the ageing eye could contribute to the degeneration of photoreceptors. Thus, a 
decreased concentration of PEDF within the old Wistar retina due to a 
malfunctioning RPE layer might contribute to the observed degeneration 
including the loss of photoreceptor cells.  
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It is unlikely, however, that the observed decrease in RPE staining 
intensity for PEDF and the decreased PEDF content of Wistar retinas are the 
sole reason for the observed degeneration and one can only speculate why at 
this age, only the Wistar retina showed signs of degeneration. One explanation 
could be the lack of pigmentation in Wistar eyes. Melanin, a dopa derived 
pigment, acts as an optical aid to avoid light scattering, is known to function as 
an antioxidant, contributes to the protection of photoreceptors from light damage 
and has been implicated to play a role during development of the retina (Sanyal 
et al., 1988; Jeffery, 1997). Consequently, retinas from albino Wistar rats were 
shown to be more susceptible to ischemic damage than pigmented retinas (Safa 
and Osborne, 2000). It is therefore likely that the lack of pigmentation is also an 
important factor that contributes to the observed degeneration of the retina.  
Taken together, a naturally occurring decrease of PEDF in complete eyes 
at high age in combination with a lower PEDF content in the albino retina might 
not be able to protect photoreceptors from extensive light-induced cell damage, 
and could therefore contribute to the degeneration of the albino eye at high age.  
 
In summary one can say that the downregulation of PEDF in the entire 
aging eye appears to be a normal process. Western blot results of whole eyes 
furthermore indicate that there seem to be strain specific differences in the PEDF 
content at old age. The downregulation of PEDF in the old albino retina might be 
a contributing factor to the observed retinal degeneration as indicated by 
Western blot results of retinas and the reduced staining of RPE cells at high age.  
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IV.3. VEGF/PEDF ratio and VEGF protein expression during early postnatal 
angiogenesis of the rodent eye.  
The retinal vasculature in the rodent is unique in respect to its postnatal 
development. During vasculogenesis a primitive vascular plexus forms de novo 
and a superficial layer of vessels forms first and originates from the optic nerve. 
The vessels spread outwards radially as a network of capillaries and reach the 
edge of the retina in the second postnatal week. In a second phase, a deep 
vascular system is formed by sprouting perpendicularly as far as the inner 
nuclear layer and extends branches parallel to the retinal surface. Thus, between 
P1 and P18, a gradient of vascular development and subsequent remodeling 
takes place between the optic disc and the retinal margin, as well as the 
superficial and deep layers.  
VEGF is a major mediator of vascularisation in the eye and an important 
growth factor during the development of the retina. It is capable of initiating 
angiogenesis by promoting endothelial cell proliferation as well as 
chemoattraction, and maintains the viability of immature blood vessels (Alon et 
al., 1995). VEGF also facilitates pericyte recruitment of immature vessels which 
appears to be an important step in the maturation of vessels (Benjamin et al., 
1998). 
Besides its neuroprotective effect, PEDF also functions as a strong anti-
angiogenic factor in the eye (Tombran-Tink and Barnstable, 2003b). The protein 
inhibits the migration of endothelial cells in vitro (Duh et al., 2002) and was more 
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effective than other angiogenesis inhibitors such as angiostatin, thrombospondin-
1, and endostatin, placing it among the most potent natural inhibitors of 
angiogenesis (Dawson et al., 1999). PEDF is probably responsible for the normal 
avascularity of several ocular compartments and addition of anti-PEDF 
antibodies to rat corneas was shown to induce the invasion of new vessels into 
these corneas (Dawson et al., 1999). Loss of its expression leads to increased 
ischemia-induced retinal neovascularisation (Dawson et al., 1999) and treatment 
of mice with systemic or intra-ocular injections of recombinant PEDF results in a 
significant decrease of choroidal and retinal neovascularisation (Mori et al., 2001; 
Stellmach et al., 2001; Duh et al., 2002).  
It has been shown that under pathological conditions such as diabetic 
retinopathy, retinopathy of prematurity, macular degeneration and glaucoma, 
regions of the retina become ischemic. Ischemia increases the production of 
angiogenic stimulators and decreases the production of angiogenic inhibitors, 
thereby breaking the balance between positive and negative regulators of 
angiogenesis. It is therefore thought that alterations in the ratio of VEGF to PEDF 
may be an underlying cause of pathological neovascularisation (Gao et al., 2001; 
Tombran-Tink and Barnstable, 2003a).  
Thus far, little is known about the relative protein ratio of VEGF to PEDF in 
the normal eye during physiological angiogenesis early in postnatal development. 
It is hypothesized that during early developing life angiogenic stimulators 
outweigh angiogenic inhibitors (see also Fig. I.5.2.1; Gao et al., 2002a). To test 
the hypothesis that the VEGF/PEDF ratio is similarly elevated during early 
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postnatal angiogenesis, as has been shown in pathological conditions, the 
relative protein content of VEGF to PEDF was measured in complete rat eyes 
from birth until 3 months and the protein location of VEGF was compared to the 
one of PEDF by immunohistochemical means.  
 
Results:  
The same samples that were used to measure the PEDF content in 
complete rat eyes were used to calculate the overall amount of VEGF (Fig. 
IV.3.1). As a positive control, several concentrations of recombinant rat VEGF 
were loaded onto the gel. VEGF showed a migration pattern similar to the 
molecular weight of the protein in the eye samples and was slightly above 20 
kDa. Omitting the primary antibody showed no staining (data not shown).  
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Fig. IV.3.1) VEGF content of complete Long Evans and Wistar rat eyes from birth 
until 3 months of age. 
A) 50 µg of complete eye homogenates of animals between PO and 3 months 
were analyzed by Western blot analysis. VEGF was normalized to the 
average actin signal at each age and then compared to a standard curve of 
VEGF (2.5-10 ng, not shown). Data are shown as mean ± SEM.  Black bars 
represent eyes of Long Evans rats and white bars Wistar eyes. A Mann-
Whitney-U test showed that overall there was no significant difference in the 
VEGF content  of eyes between the two rat strains (P=0.576, n=85), although 
at 3 months Wistar eyes contained significantly more VEGF than Long Evans 
eyes (P=0.027, n=17). A Spearman Rank test showed that overall there was 
a significant increase in VEGF with age in both strains (Long Evans: n=41, 
r=0.794, P<0.000; Wistar: n=44, r=0.915, P<0.000). Significant changes 
between rat strains are indicated by asterisks.  
B) Underneath the graph a Western Blot of one representative sample per age is 
shown for VEGF and actin. VEGF in samples migrated at similar height as the 
positive control (lane 1, 2.5 ng) and was detected slightly above 20 kDa. 
 
The overall VEGF content in the eye was the lowest at birth (Long Evans = 
53±2.6 pg/µg and Wistar = 58±2.0 pg/µg protein) and there was no significant 
difference between the rat strains at any of the ages tested, except at 3 months 
when Wistar eyes contained slightly, but significantly more VEGF than Long 
Evans eyes (Long Evans 101.2±2.6 pg/µg protein, Wistar 112±3.6 pg/µg protein, 
P=0.025, n=17). VEGF levels steadily increased from birth on and at 3 months 
Long Evans and Wistar eyes contained 1.91 and 1.93 times more VEGF than at 
birth, respectively. A Mann-Whitney-U test showed that overall there was no 
significant difference in the VEGF content between strains (P=0.576, n=84), but a 
significant change of VEGF was observed with increasing age for both strains 
(Spearman rank correlation for Long Evans n=41, r=0.794, P<0.000 and Wistar 
n=44, r=0.915, P<0.000). Wistar rat eyes contained a total of 2.9% more VEGF 
compared to Long Evans eyes.  
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PEDF and VEGF values from individual eye samples were used to 
calculate the ratio between VEGF and PEDF (Fig. IV.3.2). The VEGF/PEDF ratio 
was the lowest at birth and there was 22-24 times more PEDF than VEGF 
present in Wistar and Long Evans rat eyes, respectively. Between birth and two 
weeks of age, this ratio doubled and increased significantly (P<0.000, n=30), but 
remained fairly stable until 3 months and during this time there was 10.7-12.8 
times more PEDF than VEGF in eyes of both rat strains. Between birth and 2 
months, there was no significant difference in the VEGF/PEDF ratio when 
comparing the two rat strains at each individual age. At 3 months, however, there 
was a significant difference in the VEGF/PEDF ratio between Long Evans and 
Wistar rats (P=0.036, n=17), since Wistar eyes contained slightly less PEDF, but 
somewhat more VEGF than Long Evans eyes. A Spearman rank correlation 
showed a significant overall effect of age in respect to the VEGF/PEDF ratio for 
Long Evans (n=41, r=0.445; P=0.004) and Wistar eyes (n=43, r=0.6; P<0.000) 
due to the shift in the VEGF/PEDF ratio after birth. Between P14 and 2 to 3 
months there was, however, no significant effect of age on the VEGF/PEDF ratio 
for Wistar (n=29, r=0.169; P=0.384) and Long Evans eyes (n=34, r=0.02; 













Fig. IV.3.2) VEGF/PEDF ratio of complete Long Evans and Wistar rat eyes from 
birth until 3 months of age. 
The estimated amount of VEGF and PEDF of each sample was used to calculate 
the VEGF/PEDF ratio. Data are shown as mean ± SEM.  Black bars represent 
eyes of Long Evans rats and white bars Wistar eyes. A Mann-Whitney-U test 
showed that overall there was no significant difference in the VEGF/PEDF ratio 
between Long Evans and Wistar eyes (P=0.403, n=84), although at 3 months the 
VEGF/PEDF ratio was significantly higher in Wistar eyes compared to Long 
Evans eyes (P=0.036, n=17). Overall, there was a correlation between the 
VEGF/PEDF ratio and age for both strains (Spearman rank test for Wistar: n=43, 
r=0.6, P<0.000 and Long Evans: n=41, r=0.445, P=0.004). However, between 
P14 and 2 to 3 months, respectively, there was no significant effect of age on the 
VEGF/PEDF ratio in Wistar (n=29, r=0.168, P=0.384) and Long Evans eyes 




To investigate the localization of VEGF protein in the eye, retinas at birth, 
2 weeks and 3 months old Long Evans and Wistar rats were stained for VEGF 
(Fig. IV.3.3) and compared to the appropriate IgG controls, which were negative 
in all cases (see Fig. IV.1.2 G).  
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Fig. IV.3.3) DAB immunohistochemical staining of Long Evans (left panel) and 
Wistar (right panel) retinas for VEGF at P0 (A and B), P14, (C and D) and 3 
months (E and F) of age. The pictures show the weak staining of vessels on the 
surface of the retina (arrows) for VEGF, as well as the clear reaction of RGC 
somata for VEGF in both strains. Abbreviations: CC, choroid; INL inner nuclear 
layer; INS, inner synaptic layer; ONL, outer nuclear layer; OSL, outer synaptic 
layer; NBCL, neuroblastic cell layer; PhR, photoreceptors; RGC, retinal ganglion 
cells; RPE retinal pigment epithelial cells; SCL, sclera;  
 
 
Since no obvious differences in staining location or staining intensities for 
VEGF protein were observed between the two rat strains, the following 
paragraph describes a general staining of both strains. Although VEGF staining 
was already fairly strong at birth, it appeared to be the most intense at two weeks 
of age and decreased again somewhat in adulthood.  
As for PEDF, the RGC layer intensely stained for VEGF. Most cells of the 
INL stained for VEGF, although not quite as prominent as in the RGC layer. 
Comparable to the PEDF signal, cells in the ONL showed a slight VEGF signal at 
2 weeks of age which decreased however to nearly nondetectable levels at 3 
months of age. Like PEDF, VEGF stained photoreceptors relatively intense at 2 
weeks of age, which also decreased to nearly nondetectable levels at 3 months 
of age. Comparably to PEDF, the RPE layer appeared to increase in VEGF 
staining after birth in both strains. Similarly to PEDF, a VEGF signal was 
detected in the choroid at all ages.  
PEDF stained blood vessels in retinas of both strains as indicated by 
double labeling with the vessel marker Glut-1 (Fig. IV.3.4). However, no 
colocalization of VEGF and the vessel marker Glut-1 could be observed, 
although both proteins were in very close vicinity, especially at the surface of the 
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retina (Fig. IV.3.5). Vessels within the retina however clearly were only stained 




Fig. IV.3.4 Fluorescent double labeling of a vessel with PEDF (A) and Glut-1 
antibody (B) of a 3 month old Wistar eye. Image (A) and (B) were super imposed 
which shows the double labeling of a vessel with PEDF and Glut-1 antibody as 




Fig. IV.3.5 Fluorescent double labeling of a vessel with VEGF (A) and Glut-1 
antibody (B) of a 3 month old Long Evans eye. Image (A) and (B) were super 
imposed as shown in (C) which shows the close localization of VEGF and Glu-1 




The results of this study show that Wistar and Long Evans retinas similarly 
stained for VEGF protein from birth until young adult age in regards to staining 
location and intensity, suggesting that angiogenic stimulators do not significantly 
outweigh angiogenic inhibitors during physiological angiogenesis that occurs in 
early postnatal development. Previous studies have shown that VEGF mRNA 
parallels retinal vascularisation in a temporal and spatial manner in rat neonates 
(Murata et al., 1996; Yi et al., 1998), although low VEGF protein levels can still 
be detected after completion of vascularisation (Chan et al., 2000). In these 
works, cells expressing VEGF in the retina included the RPE layer, INL and RGC 
layer, which were also labeled in this study. In the present study, VEGF protein 
was readily detectable also in adulthood. However, VEGF labeling appeared to 
be the most intense at 2 weeks of age, at a time when the vascular network is 
not quite complete yet, which is in line with previous reports (Murata et al., 1996; 
Yi at al, 1998). 
At birth, complete eyes contained far more PEDF than VEGF and the 
VEGF/PEDF ratio even increased with age which would implicate a more 
stimulatory environment for vessel growth. Thus, the data of complete rodent 
eyes do not support the hypothesis that during normal vessel growth a high 
VEGF to PEDF ratio is needed for vessels to grow as has been suggested before 
and has been shown to be the case in pathological conditions. However, one 
needs to be careful interpreting these results since the whole eye contains 
vascularised areas and compartments that are devoid of vessel (see also Fig. 
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I.5.1.1). Furthermore, PEDF accumulates to different degrees in different 
compartments of the eye and the VEGF content in the retina was not tested. 
Also, the employed antibodies could have different sensitivities for the stained rat 
tissue and the employed positive control. This would however only affect the 
absolute concentrations of the growth factors, but not the change of their 
respective ratio over time.  
If immunohistochemical stainings in fact mirrored the PEDF and VEGF 
content in the retina, then at birth rodent retinas contained about equal amounts 
of both growth factors, or possibly slightly more VEGF. This would indicate more 
of a stimulatory environment for vessel growth compared to data from complete 
eyes and be in support of the above hypothesis.  
However, outgrowing vessels on the surface of the retina just after birth 
clearly stained strong for PEDF, which would not be in line with the idea of PEDF 
as an antiangiogenic agent. Although on the surface of the retina, VEGF stained 
structures in the close vicinity of vessels that were most likely glia cells, vessels 
themselves were not labeled for VEGF. Furthermore, photoreceptor cells stained 
stronger for VEGF than for PEDF, although it has been shown that PEDF has a 
neuroprotective effect on photoreceptor cells (Cao et al., 2001) and normally 
there are no vessels in this layer. 
One hypothesis that might explain these observations would be that at 
early postnatal age, PEDF might function more as a neuroprotective factor in the 
retina rather than an antiangiogenic agent and/or that the function of PEDF 
changes over time. This idea is supported by several findings. First, it has been 
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shown that depending on the phosphorylation status of PEDF, the protein can 
function as an antiangiogenic factor or a neurotrophic agent (Maik-Rachline et 
al., 2004). Thus, depending on the existence of specific intra- and extracellular 
protein kinases PEDF can have different effects. Second, PEDF was proven to 
even have a synergistic action on VEGF-induced bovine retinal endothelial cell 
proliferation when cells were previously cultured with VEGF. PEDF however had 
an inhibitory effect on cell growth when cells were not previously stimulated by 
VEGF (Hutchings et al., 2002). Thus, depending on the phenotype PEDF can 
exert opposite effects on endothelial cells. This idea is supported by data that 
show that during pathological neovascularisation PEDF only induced apoptosis 
of endothelial cells that are activated and participate in neovascularisation, and 
that PEDF did not harm existing vessels (Stellmach et al., 2001). Third, PEDF is 
even able to protect cultured retinal pericytes surrounding the microvasculature 
from advanced glycosylation end product-induced apoptosis through its 
antioxidative properties (Yamagishi et al., 2002). All these data therefore indicate 
that PEDF may not necessarily always act as an antiangiogenic agent on vessel 
growth and could have even a stimulatory effect during physiologically occurring 
angiogenesis. Clearly, more research needs to be done in order to find out under 
which conditions PEDF has an inhibitory or even stimulatory effect on endothelial 
cell growth.  
 
In total, there was a high degree of overlap in the location of the two 
growth factors in the retina. Both growth factors seemed to stain many of the 
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same cell types and were located in close vicinity to each other, suggesting that 
their regulation may be closely correlated with each other in many cell types. In 
fact, intravitreal injections of the angiogenic inhibitor plasminogen kringle 5 both 
downregulates VEGF and upregulates PEDF in the entire retina, as well as in 
cultured retinal vascular cells (Gao et al., 2002b). Furthermore, VEGF secreted 
by RPE cells upregulates the expression of PEDF via VEGFR1 in an autocrine 
manner (Ohno-Matsui et al., 2003), indicating that PEDF and VEGF protein 
expression are closely linked. 
 
In conclusion, the VEGF and PEDF protein content of complete eyes and 
the immunohistochemical stainings of retinas do not support the idea that during 
angiogenesis that occurs early in postnatal development angiogenic stimulators 
significantly outweigh angiogenic inhibitors. However, further experiments that 
focus more on the VEGF and PEDF content in the retina will be needed to 
answer this question in more detail. The data of this study suggest that the 
expression of VEGF and PEDF may be closely correlated during times of 
physiologically occurring angiogenesis in the rodent eye, and that under normal 
physiological conditions PEDF may function more as a neurotrophic and 
neuroprotective factor rather than an antiangiogenic factor in the retina.  
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IV.4. Is a change of the VEGF/PEDF ratio and VEGF protein expression 
related to the observed neovascularisation in old Wistar eyes? 
 
Introduction: 
In the eye ischemic events underlie the progression of several blinding 
diseases. Low oxygen levels have been shown to increase the production of 
VEGF which is known to be a key angiogenic factor involving neovascularisation. 
On the other hand, there is evidence that PEDF induces apoptosis of endothelial 
cells that are participating in neovascularisation (Stellmach et al., 2001). It has 
been previously shown that the balance of VEGF and PEDF is disturbed during 
pathological neovascularisation (Ohno-Matsui et al., 2001; Gao et al., 2001), and 
there are indications that species specific alterations in the ratio of VEGF to 
PEDF may be the reason for the high sensitivity of some rat strains to 
neovascularisation after hyperoxia (Gao et al., 2002a).  
The growth of neovascular membranes from the choroid into the retina is a 
major cause of blindness in AMD. Besides retinal degeneration that has been 
linked to AMD, old Wistar eyes also showed signs of neovascularisation while 
age-matched Long Evans retinas appeared morphologically intact. To test the 
hypothesis that a change in the VEGF/PEDF ratio might be related to the 
observed neovascularisation and degeneration at old age, the VEGF/PEDF ratio 
was measured in Wistar and Long Evans eyes between 3 and 22 months of age 
and the VEGF protein location was compared to the one of PEDF in 15-17 
months old rat retinas by immunohistochemical means. Since VEGF A has been 
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found to be the major form of VEGF responsible for neovascularisation 




As previously shown in figure IV.3.1, the VEGF content of complete rat 
eyes significantly increased and roughly doubled between birth and 3 months of 
age. After 3 months however, a Kruskal Wallis test showed that age had no 
significant effect on the VEGF content of combined Long Evans and Wistar eyes 
any more (P=0.094, n=51), and at 22 months, Long Evans and Wistar eyes 
contained 2.45 and 1.96 times more VEGF than at birth, respectively (Fig. 
IV.4.1). When rat strains were tested individually, a Spearman Rank test 
indicated that age still had an effect on the VEGF content in Long Evans eyes 
(n=26, r=0.654, P<0.000), but not in Wistar eyes (n=25, r=0.794, P=0.055). 
However, no significant difference could be found in between rat strains at any 
age tested. In total, Wistar rat eyes contained 2.8% more VEGF compared to 












Fig IV.4.1) VEGF content of complete Long Evans and Wistar rat eyes from 3 
months until high age. 
A) 50 µg of complete eye homogenates of animals between 3 and 22 months 
were analyzed by Western blot analysis. VEGF was normalized to the 
average actin signal at each age and then compared to a standard curve of 
VEGF (2.5-10 ng, not shown). Data are shown as mean ± SEM.  Black bars 
represent eyes of Long Evans rats and white bars Wistar eyes. A Kruskal 
Wallis test showed that for Long Evans and Wistar eyes combined, overall 
there was no significant difference in the VEGF content over age (P=0.094, 
n=51). However, when testing the strains separately, a Spearman Rank test 
showed that there was a correlation between the VEGF content in Long 
Evans eyes and age (n=26, r=0.654, P<0.000), but not for Wistar eyes (n=25, 
r=0.055, P=0.794). Significant changes between rat strains are indicated by 
asterisks.  
B) Underneath the graph a Western Blot of one sample per age is shown for 
VEGF and actin. PEDF samples migrated at the same height as the positive 
control (lane 1, 2.5 ng) and were detected slightly above 20 kDa. 
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As has been shown before, the VEGF/PEDF ratio was the lowest at birth, 
but remained fairly stable until 3 months (Fig. IV.3.2 and Fig. IV.4.2). At older 
ages however, the VEGF/PEDF ratio increased dramatically due to decreasing 
PEDF and slightly increasing VEGF levels, so that at 20-22 months there was 
only 2.2 and 3 times more PEDF than VEGF in Long Evans and Wistar eyes, 
respectively, compared to 24-22 times more PEDF than VEGF at birth (Fig. 
IV.4.2). At 8 and 15 months, the VEGF/PEDF ratio of Long Evans eyes was 
significantly higher than that of Wistar eyes (8 months: P=0.024, n=18; 15 
months: P=0.024, n=9), since Wistar eyes contained significantly more PEDF 
than Long Evans eyes. Between 3 and 22 months, a Spearman rank correlation 
showed a significant overall effect of age on the VEGF/PEDF ratio for Long 
Evans (n=24, r=0.74, P<0.000) and Wistar eyes (n=26, r=0.906, P<0.000) which 
increased over time.  
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Fig. IV.4.2) VEGF/PEDF ratio of complete Long Evans and Wistar rat eyes from 
birth until old age. 
The estimated amount of VEGF and PEDF of each sample was used to calculate 
the VEGF/PEDF ratio. Data are shown as mean ± SEM.  Black bars represent 
eyes of Long Evans rats and white bars Wistar eyes. A Mann-Whitney-U test 
showed that overall there was no significant difference in the VEGF/PEDF ratio 
between Long Evans and Wistar eyes (P=0.756, n=117), although at 3, 8 and 15 
months there was a significant difference in the VEGF/PEDF ratio between 
strains (3 months: P=0.036, n=17; 8 months: P=0.024, n=18; 15 months: 
P=0.024, n=9). Overall, the VEGF/PEDF ratio significantly increased with age for 
both strains (Spearman rank test for Wistar: n=58, r=0.807; P<0.000 and Long 
Evans: n=59, r=0.809; P<0.000). Significant changes between rat strains are 
indicated by asterisks.  
 
According to the VEGF/PEDF ratio of complete eyes, Long Evans rats 
should be more susceptible to neovascularisation than Wistar rats. Therefore, 
retinas from 15-17 months old Long Evans and Wistar eyes were stained for 
VEGF to test for any strain specific differences within the retina in more detail. 
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Stainings were compared to the appropriate IgG controls, which were negative in 
all cases (see Fig. IV. 2.2). As has been shown already in figure IV.2.2, vessels 
transversed the entire Wistar retina in some areas indicating the growth of new 
blood vessels, which could not be observed in Long Evans retinas. Furthermore, 
only the choroid of Wistar retinas contained a high amount of blood vessels with 







Fig. IV.4.3) DAB immunohistochemical staining of 15-17 months old Long Evans 
(A) and Wistar (B) retinas with VEGF antibody.  
The pictures show the decreased staining of the RPE layer as well as somata of 
RGC and INL cells in the old Wistar retina compared to the Long Evans retina. 
The appearance of fiber-like structures in the ISL is indicated by arrow heads. 
Large vessels in the choroid of Wistar retinas are marked by arrows. 
Abbreviations: CC, choroid; INL inner nuclear layer; ISL, inner synaptic layer; 
ONL, outer nuclear layer; PhR, photoreceptors; RGC, retinal ganglion cells; RPE 






As for PEDF, the RGC layer intensely stained for VEGF in both rat strains. 
In old Wistar retinas one could however observe a shift of VEGF staining from 
RGC somata and from somata from the INL to GFAP stained fibers that 
appeared in the RGC layer, ISL and INL of the retina (Fig. IV.4.4 and IV.4.3). 
This shift in VEGF staining location was much less pronounced in old Long 
Evans retinas where VEGF/GFAP double labeled fibers could only be detected 
on the surface of the retina, especially in the vicinity of large vessels (Fig. IV.4.5). 
No GFAP/PEDF double labeling could be detected in any of the rat strains at old 





Fig. IV.4.4. Fluorescent double labeling of an old Wistar retina with VEGF (A) and 
GFAP antibody (B). The image shows the lack of VEGF stained somata in the 
INL. An overlay of the VEGF and GFAP staining is seen in (C) which shows a 
complete overlap of VEGF and GFAP stained structures in old Wistar retinas as 
shown by the yellow color. Abbreviations: INL inner nuclear layer; ONL, outer 
nuclear layer; RGC, retinal ganglion cells; RPE retinal pigment epithelial cells;  
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Fig. IV.4.5. Fluorescent double labeling of an old Long Evans retina with VEGF 
(A) and GFAP antibody (B). An overlay of the VEGF and GFAP staining is shown 
in (C) which shows that in old Long Evans retinas VEGF/GFAP double labeled 
structures were only located at the surface of the retina as indicated by the 
yellow color.  Abbreviations: INL inner nuclear layer; ONL, outer nuclear layer; 




Fig. IV.4.6. Fluorescent double labeling of an old Wistar retina with PEDF (A) and 
GFAP antibody (B). A nuclear staining of the same area with Hoechst is shown in 
(C) and an overlay of the PEDF and GFAP staining in (D). The figure shows that 
there was no colocalization of PEDF and GFAP labeled structures anywhere in 
the retina.  Abbreviations: INL inner nuclear layer; ONL, outer nuclear layer; 
RGC, retinal ganglion cells; RPE retinal pigment epithelial cells;  
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Fig. IV.4.7. Fluorescent double labeling of an old Long Evans retina with PEDF 
(A) and GFAP antibody (B). A nuclear staining of the same area with Hoechst is 
shown in (C) and an overlay of the PEDF and GFAP staining in (D). The figure 
shows that there was no PEDF/GFAP colocalization, although GFAP positive 
astrocytes were in close vicinity to PEDF positive vessels (arrows). 
Abbreviations: INL inner nuclear layer; ONL, outer nuclear layer; RGC, retinal 
ganglion cells; RPE, retinal pigment epithelial cells;  
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 In Long Evans retinas the ONL and photoreceptor layer weakly stained 
for both PEDF and VEGF. A strong VEGF staining was detected in the RPE layer 
of Long Evans retinas while the VEGF labeling of RPE cells of old Wistar retinas 
had decreased a lot (Fig. IV.4.3). The VEGF signal in the choroid of old Wistar 
eyes had decreased to nearly background levels compared to 3 month old 
animals, while the same layer showed a strong staining for PEDF (see Fig. 
IV.2.2). Due to the pigmentation in Long Evans rats the staining of both growth 
factors in the choroid was difficult to determine in this strain. 
 
In summary, in general PEDF stained the same cell types and layers in 
both rat retinas at old age although with slightly changing intensities. The same 
was also true for VEGF regarding Long Evans retinas. In old Wistar retinas there 
was, however, an obvious shift in VEGF protein expression from RGC somata 
and cells of the INL to newly appearing GFAP labeled fibers in the RGC layer, 
ISL and INL.   
 
Discussion: 
Western blot results indicate that complete Wistar and Long Evans eyes 
contained similar amounts of VEGF.  In Wistar eyes, the VEGF content did not 
significantly change after young adulthood was reached, while it slightly, but 
significantly increased with increasing age in Long Evans eyes. Since 
morphologically intact Long Evans eyes even had a significantly higher 
VEGF/PEDF ratio between 8 and 15 months, they should be more susceptible to 
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neovascularisation than Wistar eyes. The data therefore suggest, that a high 
VEGF/PEDF ratio of complete eyes cannot be responsible for the observed signs 
of neovascularisation in old Wistar rats and that the two rat strains may have a 
different susceptibility to neovascularisation in regards to the VEGF/PEDF ratio.  
 
However, one needs to be careful to compare data of complete eyes with 
the retina. Since the retina contributes only a relatively small amount of PEDF to 
the overall PEDF content in the entire eye, the finding that complete eyes of old 
Long Evans rats had a high VEGF/PEDF ratio may not be contradictory to the 
hypothesis that a high VEGF/PEDF ratio in the retina (and not complete eyes) 
might be related to pathological neovascularisation. Indeed, within the retina 
there are several indications that a change in immunohistochemical staining 
patterns of VEGF and PEDF at old age might contribute to an unbalanced 
expression of the two growth factors and might therefore be related to retinal 
neovascularisation. 
First, the findings of this study that RPE cells of old Wistar retinas stained 
less for PEDF, and that Wistar retinas contained less PEDF than those of Long 
Evans rats would contribute to an increased VEGF/PEDF ratio within the Wistar 
retina.  This would be in line with the report that RPE cells produce less PEDF 
under oxidative stress, while their VEGF production is increased (Ohno-Matsui et 
al., 2001).  
Second, old Wistar retinas also showed an obvious shift in VEGF protein 
expression from RGC somata and cells of the INL to GFAP labeled fibers.  GFAP 
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has been previously shown to label Muller glia cells in the eye during retinal 
stress and in pathological states including AMD (Fan et al., 1996; DiLoreto et al., 
1995; Wu et al., 2003). The observed shift in VEGF expressing cells is also in 
line with a previous study that has shown an upregulation of VEGF in the retina 
of patients with diabetes and disciform AMD in astrocytes and Muller cells 
(Sueishi et al., 1996; Amin et al., 1997). Also, activated or VEGF expressing 
Muller cells have been associated with photoreceptor cell loss and 
neovascularisation (Amin et al., 1997; Roque and Caldwell, 1990; Perez and 
Perentes, 1994). Activation of Muller cells was also reported to occur during 
photoreceptor degeneration, and precedes retinal vascularisation in Royal 
College of Surgeons rats with inherited retinal dystrophy (Roque and Caldwell, 
1990). In Roque and Caldwell’s study RGC’s as well as RPE cells of AMD retinas 
showed an apparent decrease in VEGF expression which is in line with the data 
of this study. These reports together with the findings of the present study 
support the idea that the staining of Muller cells for VEGF is associated with the 
observed degeneration and revascularization of old Wistar retinas. It has been 
also shown that RPE removal from the retina causes degenerative changes in 
Muller cells, such as a failure to form adherents junctions with photoreceptor 
cells, suppression of glutamine synthetase expression, and, notably, the 
expression of GFAP. Interestingly, PEDF addition aborted these pathological 
changes in Muller cells including the expression of GFAP (Jablonski et al., 2001). 
Given these observations, it is likely that PEDF might also be able to reduce the 
VEGF expression of these cells. A decrease in PEDF within the retina might 
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therefore contribute to the VEGF expression of Muller glia which seems to be a 
prerequisite for retinal degeneration and revascularization.  
A third indication for an unbalanced expression of the two growth factors is 
the finding that similar to cells of the INL and RGC’s, RPE cells of old Wistar rats 
showed a strong decrease in VEGF staining and the choroid practically did not 
stain for VEGF any more. It has been shown that RPE cells preferentially secrete 
VEGF towards their basolateral side (Blaauwgeers et al., 1999) and that RPE 
cells have a decreased expression of VEGF during AMD (Roque and Caldwell, 
1990), which might explain why practically no VEGF could be localized in the 
choroid any more at old age. There is further evidence that only continuously 
administered VEGF can induce the fenestration of endothelial cells (Ribatti et al., 
2001; Eriksson et al., 2003), as is typically the case in the choroid. Thus, a lack 
of VEGF  in the choroid due to a decreased VEGF expression by RPE cells could 
potentially explain the observed widened vessels in the choroid of old Wistar 
eyes.  
Thus, in the degenerated albino retina the strength and cellular location of 
the expression of the two growth factors was not as closely correlated as 
observed in younger animals which could contribute to the observed 
degeneration and neovascularisation of the retina.  
 
In summary, one can say that although the VEGF/PEDF ratio of the entire 
eye significantly increased in both rat strains at old age, a high VEGF/PEDF ratio 
in the entire eye cannot be associated with degenerative diseases of the eye, but 
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may be a naturally occurring process at old age that could however make certain 
older individuals more susceptible to degenerative processes including 
neovascularisation. The decreased labeling of RPE cells for PEDF in old Wistar 
retinas in combination with a decrease of PEDF in the entire retina compared to 
Long Evans retinas supports the idea that a shift in the VEGF/PEDF ratio within 
the retina may be associated with the observed retinal neovascularisation as well 
as degeneration. Furthermore, the uncoupling of the protein expression of the 
two growth factors due to the observed increase in VEGF staining of glia cells in 
the old Wistar retina may be also an important indicator for retinal damage and 
may even be a prerequisite for vessel growth.  
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IV.4. Final conclusions of chapter IV 
▬ The data of this study show that the protein expression of PEDF in the entire 
eye was high at birth until young adulthood, but decreased from thereon with 
increasing age of the animal. This appeared to be a natural phenomenon 
independent of retinal degeneration or vascularisation.  
▬ Overall there was no correlation between the lack of pigmentation in Wistar 
eyes and the PEDF content of complete eyes or its protein localization within 
the retina at younger ages.  
▬ A decrease of PEDF production by RPE cells in old Wistar eyes could 
contribute to the observed reduction of PEDF within the entire retina and 
might therefore contribute to the observed retinal degeneration and 
neovascularisation.  
▬ While the protein localization of PEDF and VEGF appeared to be closely 
regulated in the healthy eye, the expression of the two growth factors was 
uncoupled during pathophysiological conditions at advanced age. These 
changes were especially evident regarding the VEGF location which shifted 
from RGC and INL cells to Muller glia cells which might contribute to a VEGF 
induced neovascularisation.  
▬ In the complete eye PEDF outweighed VEGF during early physiologically 
occurring angiogenesis, suggesting that early during development PEDF may 





▬ At old age the VEGF/PEDF ratio in entire eyes increased significantly. This 
increased ratio and the uncoupling of the location of the two growth factors at 
old age compared to birth suggest that vessel growth during normal 
physiological angiogenesis and pathological neovascularisation may be 
controlled in a different way.  
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V. PEDF protein content and localization in the rat brain during 
postnatal development. 
 
V.1. Can PEDF protein be immunolocated in the adult rat brain? 
 
Introduction: 
Several studies provide evidence that PEDF does not only have a 
neuroprotective effect on various cell types in the eye, but also on other cells in 
the CNS (Tombran-Tink and Barnstable, 2003b; Barnstable and Tombran-Tink, 
2004). The neurotrophic effect of PEDF on cells in the brain has been 
demonstrated mainly by in vitro experiments by its ability to support neuronal 
survival, to protect neurons against various neurotroxic effects and in some 
cases to induce neuronal differentiation. So far, it has been shown that PEDF 
has survival and/or differentiating effects on primary cultures of rat cerebellar 
granule neurons (Taniwaki et al., 1995 and 1997; Araki et al., 1998), immature 
primary rat hippocampal neurons (DeCoster et al., 1999), and avian and murine 
spinal motor neurons (Houenou et al., 1999; Bilak et al., 1999 and 2002). PEDF 
has also been shown to stimulate the metabolism and chemokine production of 
microglia cells and thereby indirectly inhibits the proliferation of astroglia(Yabe et 
al., 2005; Sugita et al., 1997; Takanohashi et al., 2005).  Thus far, PEDF was 
shown to have protective effects on Muller glia function in the retina and 
enhances the growth and survival of Schwann cells in the peripheral nervous 
system. Although both Muller and Schwann cells have been shown to also 
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produce PEDF (Eichler et al., 2004a and b; Crawford et al., 2001), so far, 
however, there is no evidence that PEDF has neuroprotective effects on further 
glia cells or that PEDF is produced by other types of glia cells in the brain.  
 
Previous research has shown that PEDF might be produced in the brain, 
since its mRNA was found in homogenates of various human brain areas 
(Tombran-Tink et al., 1996) and PEDF was proven to exist in CSF (Bilak et al., 
1999; Kuncl et al., 2002). However, it is also known that PEDF exits in rather 
high concentration in the blood (Peterson et al., 2003; Maik-Rachline et al., 
2004). The finding of our laboratory, that PEDF mRNA is expressed by 
monocytes, macrophages, granulocytes and dendritic cells of the blood suggests 
that PEDF may be produced by blood cells as well (see Fig. V.1.1). It is therefore 
not clear whether PEDF protein is in fact produced by cells in the CNS, or if the 
protein and its mRNA that have been found in brain homogenates is in fact 
derived from blood cells. With the exception of a PEDF immunohistochemical 
reaction of human, monkey and rat motor neurons and ependymal cells in the 
spinal cord (Bilak et al., 1999 and 2002), thus far, there are no studies about the 
specific localization of the PEDF protein in the healthy CNS during postnatal 
development. To find out more about the localization of the protein in the CNS, 
PEDF immunohistochemistry was performed to determine if there are any PEDF 
positive cells in the adult rat brain. 
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Fig. V.1.1) PEDF gene expression of human blood cells.  
PCR products of the PEDF gene (A) and the house keeping gene GAPDH (B) 
indicate PEDF gene expression in monocytes, macrophages, granulocytes and 
dendritic cells. Human hepatocytes were used as an internal positive control 
since they are known to strongly express the PEDF gene. 
During testing whether PEDF was upregulated in the brain after a trauma, it was 
discovered that PEDF increased not only in lesioned brain homogenates, but 
also in those sham-lesioned controls that occasionally contained some blood. 
Because of this finding, blood serum and mRNA of the following cells were tested 









Immunohistochemical labeling for PEDF was performed in fluorescence 
and DAB. As can be seen in figure V.1.2, the PEDF-antibody clearly labeled cells 
and vessels in the cortex and dentate gyrus of the hippocampus of a 3 month old 
Long Evans rat brain. To verify the specificity of the staining, fluorescent 
stainings were performed in parallel with the appropriate IgG control, which was 
negative (Fig. V.1.2F). As a further control, a preadsorption of the PEDF-antibody 
with an excess of PEDF protein was performed (Fig. V.1.2B and D).  
Preadsorption of the antibody completely abolished the cellular staining and 
reduced the strong staining of vessels significantly, indicating the specificity of 
the antibody staining. Stainings were performed several times with similar 
results. 
 
DAB stainings produced basically the same results as fluorescent 
stainings. Preadsorption of the antibody completely abolished cellular signals and 
strongly, but not completely reduced staining of vessels (Fig. V.1.3). As an 
internal control for the preadsorption, the nonspecific protein BSA was used in 
the same concentration as PEDF in order to verify that the excess of PEDF did 
not cause any nonspecific steric hindrance of the binding of the antibody (Fig. 
V.1.3A). This internal control showed the same results as the PEDF staining, 





In total, seven different antibodies from different species and against 
different parts of the human PEDF protein were tested by immunohistological 
means as well as Western Blot analysis. Although all antibodies showed similar 
results only one antibody produced good results in both Western blot analysis 
and immunohistochemical stainings and could be abolished by preadsorption 








Fig. V.1.2) Fluorescent PEDF immunohistochemistry in the adult rat brain (next 
page).  
Seven µm thin sagittal cryosections of a 3 month old Long Evans rat brain were 
fixed with 4% PFA and stained with a rabbit polyclonal antibody against human 
PEDF (1 ng/µl) and a secondary dk α-rbt RHOX antibody (1:400) (A, C, E). 
Controls were performed by substituting the primary PEDF antibody with the 
appropriate concentration of rbt IgG (F) or preadsorbing the primary PEDF 
antibody with a 100 times excess of PEDF protein over night and subsequent 
centrifugation (B, D) and show an abolished and dramatically reduced staining 
for PEDF, respectively. The PEDF antibody was treated the same as the 
preadsorption control but without addition of the PEDF protein. The data show 
staining of the PEDF antibody in areas of the cortex (A, B), an area between 
hippocampus and thalamus (C, D) and the dentate gyrus (E, F) and were taken 
with the same camera settings and adjusted for contrast and brightness in 
parallel. The cellular staining for PEDF is indicated by arrow heads and vessels 








Fig. V.1.3) PEDF DAB immunohistochemistry in the adult rat brain.  
Seven µm thin coronal cryosections of a 3 month old Long Evans rat brain were 
fixed with 4% PFA and immunoreacted with a polyclonal rabbit antibody against 
human PEDF (0.66 ng/µl) in the presence of 100 times excess of BSA (A). 
Further controls were performed by substituting the primary PEDF antibody with 
the appropriate concentration of rbt IgG (C) and using a preadsorbed primary 
PEDF antibody with a 100x excess of PEDF protein over night and subsequent 
centrifugation (B) which abolished and dramatically reduced staining for PEDF, 
respectively. The data show the strong PEDF staining of cells, vessels (arrows), 






Fluorescence and DAB stainings indicate that the employed PEDF 
antibody labels cells and vessels in the adult rat brain. The specificity of the 
cellular immunostaining in the brain was indicated by two different controls, both 
of which were negative. Although vessels still showed a low signal after 
preadsorption of the antibody, the signal was significantly reduced, suggesting 
that these structures also specifically stain for PEDF. Due to the intense labeling 
of vessels with PEDF, a higher dilution of the antibody in combination with an 
excess of PEDF should be performed to abolish the signal completely.  
The clear staining of cells and vessels for PEDF in the dentate gyrus of 
the hippocampus and the cortex suggests that PEDF might be produced in the 
adult rat brain or at least bind to these cells. The finding furthermore indicates 
that PEDF in the brain might not only be derived from serum or cells in the blood, 
since PEDF in the blood should not be able to pass into the brain tissue through 
the blood brain barrier.  
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V.2. What is the distribution of PEDF immunopositive cells in the adult rat 
brain?                                                                                              
In order to determine which cell types in the adult rat brain were PEDF 
positive, double stainings were performed with the neuron specific marker NeuN, 
the astrocyte marker GFAP, the oligodendrocyte marker MBP and the vessel 
markers vWF and Glut-1. Glut-1 is also used as a marker of the blood brain 
barrier and stains all vessels in the brain. 
There was a clear colocalization of the vessel markers Glut-1 (Fig. V.2.1) 
and vWF with PEDF (Fig. V.2.2). PEDF appeared to label all vessels in the entire 
brain, although with different intensities and larger vessels were stained stronger 
than smaller vessels.  
 
 
Fig. V.2.1) Fluorescent double labeling of a 3 month old Long Evans rat brain 
with PEDF (A) and Glut-1 antibody (B). The data show the weaker staining of 
smaller vessels for PEDF (right arrow) compared to larger vessels (left arrow) 





Fig. V.2.2) Fluorescent double labeling of a 3 month old Long Evans rat brain 
with PEDF (A) and vWF antibody (B). Images of PEDF and vWF stainings were 




Since PEDF mainly labeled the soma of cells and GFAP is strongly 
expressed in the ramifications of glia cells, it was difficult to determine whether 
any structures in the brain were double labeled with GFAP and PEDF (Fig. 
V.2.3). The finding that in most areas of the brain the PEDF-labeled structures 
were mainly large and round, and astrocytes have a star-shaped size and are 
relatively small suggests that in these areas of the brain astrocytes were not 
stained for PEDF and might therefore not produce and/or bind PEDF (see Fig. 
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V.2.7- V.2.14). In the corpus collosum, however, PEDF-labeled structures 
appeared to be more typical for astrocytes and it appeared as if there was 
colocalization of some GFAP positive structures with PEDF (Fig. V.2.3). A double 
labeling of PEDF with Glut-1 in the same area indicated however, that the 
majority of larger PEDF labeled structures were vessels (Fig. V.2.4). Since the 
colocalization seemed to occur only in the close vicinity of vessels (Fig. V.2.3C), 
and it is known that astrocytes are often closely wrapped around vessels, it is 
therefore likely that the apparent double labeling in these areas was no true 
colocalization and that astrocytes that are surrounding vessels also do not stain 








Fig. V.2.3) Fluorescent double labeling of the corpus collosum of a 3 month old 
Long Evans rat brain with PEDF (A) and GFAP antibody (B). Images for PEDF 
and GFAP were super imposed to show double labeling (C). Glia cell processes 
are shown in green. The presence of only a few yellow marked structures that 
were mainly in the vicinity of vessels (arrow) suggests that the majority of glia 





Fig. V.2.4) Fluorescent double labeling of the corpus collosum of a 3 month old 
Long Evans rat brain with PEDF (A) and Glut-1 antibody (B). Images for PEDF 
and Glut-1 were super imposed to show double labeling (C). The data show that 
in the corpus collosum the PEDF antibody mainly labeled vessels as indicated by 




Also, no double staining with PEDF could be detected anywhere in the 
brain with the oligodendrocyte marker MBP (Fig. V. 2.5), although both markers 
were located in close vicinity in the meningeal layers.  
               
Fig. V.2.5) Fluorescent double labeling of the olfactory bulb of a 3 month old 
Long Evans rat brain with PEDF (A) and MBP antibody (B). Oligodendrocytic 
processes are shown in green. Images for PEDF and MBP were super imposed 
and show that there were no double labeled structures, suggesting that PEDF 
may not be expressed in oligodendrocytes (C). 
 
Similar to vessels, the majority of neurons of most brain areas were clearly 
labeled for both Neu-N and PEDF (Fig. V.2.7-V.2.14). However, neuronal 
labeling was not as intense as the one of endothelial cells. The PEDF signal 
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appeared to be mainly localized in the cytoplasm of neurons and the perinuclear 
region. In some cases, such as in the olfactory bulb, it appeared as if PEDF 
especially labeled the nucleolus, since little dot-like structures could be observed 
in some neurons (Fig. V.2.6). 
 
 
Fig. V.2.6) Fluorescent staining of the olfactory bulb of a 3 month old Long Evans 
rat brain with PEDF (A) and NeuN antibody (B). Neuronal nuclei are shown in 
green. The picture shows a cell with a dot-like structure in the nucleus that is 
stained against PEDF (arrow head) suggesting that PEDF protein is localized in 
the nucleolus. 
 
It appeared that all NeuN positive cells in the entire dentate gyrus of the 
hippocampus (see also Fig. V.1.2 and V.1.3), the thalamus, the hypothalamus, 
the cortex, the striatum, the preoptic area, the midbrain, and the pons were also 
labeled for PEDF (Fig. V.2.7-V.2.13). Besides neuronal cells the pons also 
contained other PEDF positive cells that did not appear to be vessels (Fig. 
V.2.13). In the olfactory bulb, only a small number of neurons with relatively large 
somata were double labeled for NeuN and PEDF, while the smaller granule cells 
did not stain for PEDF (Fig. V.2.14 and V.2.15). The pituitary gland and the optic 
chiasm also contained PEDF positive cells that were not labeled with the 
neuronal marker NeuN or GFAP (Fig. V.16 and V.2.17), suggesting that the 
 116
labeled cells in the pituitary might be of endocrine origin. Furthermore, PEDF 
strongly stained the meninges (see Fig. V.1.2), as well as ependymal cells lining 
the ventricles and the choroid plexus (Fig. V.2.18). In fluorescent stainings, it 
could not be determined if cerebellar granule neurons stained for PEDF due to 
the small cytoplasmic content and faint signal (Fig. V. 2.19), although DAB 
stainings suggested a faint labeling of cerebellar granule cells for PEDF (Fig. V. 
2.20). 
For a better overview figure V.2.21 shows a schematic diagram of cells 






Fig. V.2.7) Fluorescent double labeling of the thalamus of a 3 month old Long 
Evans rat brain with PEDF (A) and NeuN antibody (C). Images for PEDF and the 
neuronal marker NeuN were super imposed to show double labeling of both 
antibodies (D). In the figure, double labeled cells are yellowish in appearance. An 
IgG control for PEDF is shown in the same brain area (B). The data show that in 
the thalamus all neurons stained positively for PEDF in addition to other PEDF 






Fig. V.2.8) Fluorescent double labeling of the hypothalamus of a 3 month old 
Long Evans rat brain with PEDF (A) and NeuN antibody (C). Images for PEDF 
and NeuN were super imposed as shown in (D). Cells that are double labeled for 
PEDF and the neuronal marker NeuN appear yellowish. An IgG control for PEDF 
is shown in the same brain area (B). The data show that all neurons in the 
hypothalamus stained for PEDF and NeuN in addition to other PEDF positive 






Fig. V.2.9) Fluorescent double labeling of the cortex of a 3 month old Long Evans 
rat brain with PEDF (A) and NeuN antibody (C). Images for PEDF and NeuN 
were super imposed as shown in (D). Cells labeled with both antibodies appear 
yellowish. An IgG control for PEDF in the same brain area shows lack of staining 
for the neurons (B). The figure shows that all neurons in the cortex stained 









Fig. V.2.10) Fluorescent double labeling of the striatum of a 3 month old Long 
Evans rat brain with PEDF (A) and NeuN antibody (C). Images for PEDF and 
NeuN were super imposed to show double labeling of both antibodies (D). 
Double labeled cells appear yellowish. (B) The IgG control for PEDF in the same 
brain shows no signal indicating the specificity of the staining. In the striatum all 








Fig. V.2.11) Fluorescent double labeling of the preoptic area of a 3 month old 
Long Evans rat brain with PEDF (A) and NeuN antibody(C). Images for PEDF 
and NeuN were super imposed to show that all neurons in the preoptic area 
stained positively for PEDF in addition to other PEDF positive structures (D). 
Double labeled cells appear yellowish. An IgG control for PEDF in the same brain 










Fig. V.2.12) Fluorescent double labeling of the midbrain of a 3 month old Long 
Evans rat brain with PEDF (A) and NeuN antibody (C). Images for PEDF and 
NeuN were super imposed to show that all neurons in the midbrain stained 
positively for PEDF in addition to PEDF positive vessels (arrows) (D). Double 
labeled cells appear yellowish. The IgG control for PEDF in the same brain area 







Fig. V.2.13) Fluorescent double labeling of the pons of a 3 month old Long Evans 
rat brain with PEDF (A) and NeuN antibody (C). Images for PEDF and NeuN 
were super imposed and show that basically all neurons stained positively for 
PEDF in addition to many other PEDF positive structures (D). Double labeled 
cells appear yellowish. (B) The IgG control for PEDF in the same brain area 
shows some unspecific background in this area of the brain. This was however 










Fig. V.2.14) Fluorescent double labeling of the olfactory bulb of a 3 month old 
Long Evans rat brain with PEDF (A) and NeuN antibody (B). Images for PEDF 
and NeuN were super imposed to show double labeling (D). (B) The IgG control 
in the same brain area shows some unspecific background which was however 
significantly fainter than PEDF labeled structures. The figure shows that larger 
neuronal cells of the olfactory bulb positively stained for PEDF in addition to other 







Fig. V.2.15) Fluorescent double labeling of the olfactory bulb of a 3 month old 
Long Evans rat brain with PEDF (A) and NeuN antibody (C). Images for PEDF 
and NeuN were super imposed to show that in this area of the olfactory bulb 
there was no colocalization of PEDF and NeuN (D). The IgG control for PEDF in 
the same area of the olfactory bulb shows completely negative staining (B). The 











Fig. V.2.16) Fluorescent double labeling of the pituitary gland of a 3 month old 
Long Evans rat brain with PEDF (A) and NeuN antibody (B), as well as with 
PEDF (C) and GFAP antibody (D). The PEDF positive cells in the pituitary gland 
are likely to be of non-neuronal and non-astrocytic origin because they did not 
react positively with the NeuN or GFAP antibody suggesting that the PEDF 




Fig. V.2.17) Fluorescent double labeling of the optic chiasm of a 3 month old 
Long Evans rat brain with PEDF (A) and NeuN antibody (B). The PEDF positive 
cells in the optic chiasm are likely to be of non-neuronal origin because they did 






Fig. V.2.18) DAB staining of the third ventricle of a 3 month old Long Evans rat 
brain with PEDF antibody (A) and the appropriate IgG control (B). There is strong 
PEDF staining of ependymal cells lining the ventricle walls (arrow heads) and of 
the choroid plexus (arrows) with the PEDF antibody suggesting that PEDF may 







Fig. V.2.19) Fluorescent double labeling of the cerebellum of a 3 month old Long 
Evans rat brain with PEDF (A) and NeuN antibody (C). Images for PEDF and 
NeuN were super imposed and show that there was no colocalization of PEDF in 
the smaller granular neurons of the cerebellum (D). The IgG control for PEDF in 
the same brain area shows a relatively high general background staining that is 
comparable to that of the PEDF antibody staining, suggesting that the fainter 







Fig. V.2.20) DAB staining of the cerebellum of a 3 month old Long Evans rat 
brain with PEDF antibody (A) and the appropriate IgG control (B). Arrow heads 
mark the location of cerebellar granule neurons. The data shows that cerebellar 
granule neurons were weakly labeled for PEDF with this technique, while 




                    
Fig. V.2.21) Schematic overview of PEDF labeled cells in the adult rat brain. 
Black stars indicate neuronal cells that stained for PEDF while blue stars show 
granular neurons that either did not label for PEDF or it could not be determined 
for sure if they were PEDF positive. PEDF labeled cells that were of non-
neuronal origin and were not glial cells are indicated by red stars. Since PEDF 




PEDF immunohistochemistry and cell specific double labeling indicate that 
all endothelial cells lining the vascular walls and most neurons were positive for 
PEDF suggesting that vessels and neurons of most brain areas might produce 
and/or bind PEDF, while oligodendrocytes were not positive for PEDF. In the 
majority of brain areas it was evident that PEDF also did not label astrocytes as 
indicated by PEDF/GFAP double labeling. In certain areas including the corpus 
collosum and ventricles, PEDF and GFAP labeled structures were in so close 
vicinity that it could not be excluded for sure that some GFAP positive cells were 
also labeled for PEDF. To examine this possibility in more detail, electron 
microscopy would have to be performed.  
Since the rather fast secretion of PEDF from the cell has caused 
difficulties in the visualization of the protein in the cell in some cases (Kozaki et 
al., 1998), it cannot be determined with this method whether these cells just bind 
PEDF or also produce PEDF. Bilak and colleges (1999) have shown however 
that PEDF positive motor neurons and ependymal cells in the spinal cord also 
express the transcript, indicating that PEDF may act as an autocrine factor in 
these cells. It is therefore possible that the stained cells that were observed in 
this study might also produce PEDF. The fact that PEDF positive endothelial 
cells are also known to produce PEDF (Aparicio et al., 2005; Matsuoka et al., 
2004) furthermore suggests that other PEDF labeled structures might produce 
PEDF as well. To answer this question for sure in situ hybridization would have 
to be performed.  
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Location of PEDF staining in the brain: 
Since PEDF has been shown to have protective effects on various 
neuronal cell types, promotes neurite outgrowth of some neuronal types, and has 
been shown to modulate vessel growth, it is not surprising that neuronal and 
endothelial cells stained for PEDF and is in support of the known effects of 
PEDF. The presented data are also in line with previous reports that have shown 
PEDF gene expression and protein labeling of endothelial cells (Aparicio et al., 
2005; Matsuoka et al., 2004) and neurons (Bilak et al., 1999 and 2002, Houenou 
et al., 1999; Yamagishi et al., 2004). In the majority of the investigated brain 
areas, PEDF seemed to label all neurons and potentially also other cells that 
were not of neuronal, astrocytic or oligodendrocytic origin. In the olfactory bulb 
(and possibly also the cerebellum), granule neurons did not obviously stain for 
PEDF and only some neuronal cells of larger size were labeled for PEDF. PEDF 
however also labeled other non-neuronal cells that were not of endothelial origin, 
suggesting that PEDF may possibly have additional functions in these brain 
areas.  
 In most brain areas it was clear that PEDF did not label astrocytes, nor 
was there a double labeling with oligodendroglia anywhere in the brain. Thus far, 
there are no indications that PEDF is produced by astrocytes in the brain and 
Bilak and colleagues (1999) also could not detect any PEDF mRNA expression 
in glial cells of the spinal cord. However, PEDF production has been reported by 
Schwann cells of neuroblastoma (Crawford et al., 2001) and by Muller glia of the 
retina (Eichler et al., 2004a and b). PEDF has also been shown to affect the 
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metabolism of microglia (Takanohashi et al., 2005; Sugita et al., 1997) which can 
indirectly affect the proliferation of astroglia (Sugita et al., 1997). PEDF, however, 
appears to be able to directly induce proinflammatory genes in neonatal 
astrocytes through the activation of NF-kappaB and CREB, but has very little 
effect on adult astrocytes (Yabe et al., 2005). Thus far, a preliminary report has 
shown that PEDF immunoreactivity of astrocytes could only be detected in 
patients with Alzheimer’s disease (Yamagishi et al., 2004). All these data suggest 
that astrocytes might be able to react to PEDF only under certain conditions, but 
might not be able to produce PEDF themselves. Thus far there is no proof yet 
that under normal physiological conditions PEDF has any effects on astrocytes in 
the adult brain and that astrocytes produce PEDF. This might explain why 
astrocytes were not visualized by immunohistochemical means in the adult brain 
under physiological conditions. 
 
In addition to endothelial cells and neuronal cells, PEDF also stained 
ependymal cells. Ependymal cells line the ventricles of the brain, the choroid 
plexus and the central canal of the spinal cord. PEDF immunoreactivity as well 
as in situ hybridization of ependymal cells have been shown previously (Bilak et 
al., 1999). Since PEDF also exists in the CSF, it is likely that the secretable 
protein is derived from ependymal cells of ventricles and choroid plexus. 
Additionally, PEDF in the CSF might be also derived from brain tissue, since 
there is no real barrier between the intercellular spaces of the brain and the CSF. 
Because PEDF levels of the CSF have been found to be elevated in amyotrophic 
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lateral sclerosis patients (Kuncl et al., 2002), it would be interesting to know if the 
transcript is elevated in ependymal cells as well as other brain cells, and if in this 
condition PEDF is elevated as a neuroprotective means to counter the 
degenerative effects.  
Apart from endothelial, neuronal and ependymal cells, PEDF also labeled 
NeuN-negative cells in the olfactory bulb, the pituitary, the optic chiasm, the pons 
and possibly also in the corpus collosum that were not of glial or endothelial 
origin as determined by double labeling and typical appearance of cells. PEDF 
binding has been previously shown in small non-neuronal cells of spinal cord 
slices (Bilak et al., 2002). Thus, it appears likely that PEDF could be produced by 
and/or affect further cell types besides neuronal, endothelial and ependymal 
cells. Further experiments including triple labeling will have to be performed in 
order to find out which type of cells these could be. 
 
Function of PEDF in the brain: 
The wide distribution of PEDF protein in neurons of different brain areas 
suggests that many different neuronal phenotypes seem to have a PEDF 
receptor, and that it is likely that PEDF has neurotrophic and/or neuroprotective 
effects on all these neurons. Thus far, it has been shown that PEDF has 
neuroprotective effects on immature hippocampal neurons. This study shows 
however that neurons in the adult hippocampus stained for PEDF, suggesting 
that PEDF might also have some kind of neuroprotective effect on mature 
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hippocampal neurons as well. If staining of neurons for PEDF in fact indicates 
that PEDF might have some kind of neuroprotective or neurotrophic effect, or 
might keep neurons in a differentiated state, then most neurons in the brain 
would be responsive to PEDF in some kind of way. Thus far, this has been 
shown for at least hippocampal and motor neurons, and possibly also cerebellar 
granule neurons (see also chapter IV question 4). Depending on the neuronal 
origin, there seem to be however slight differences against the type of insult that 
PEDF protects these cells from, suggesting that PEDF may activate different 
cellular mechanisms in different neuronal phenotypes and during different stages 
of development.  
The finding that PEDF protein can be located in two neurogenic regions of 
the brain, the dentate gyrus and the subventricular zone, suggests that PEDF 
might potentially also affect neurogenesis. This idea is supported by preliminary 
unpublished data from our laboratory that suggest that PEDF might influence the 
VEGF-induced replication of neuronal stem cells of the subventricular zone in 
vitro and in vivo. This finding is in line with previous reports of PEDF as a 
differentiating factor. Since PEDF has been also positively linked to cells entering 
the G0 state, PEDF might work by reducing the number of cells that enter the S-
phase of the cell cycle, thereby interrupting proliferation and inducing the cell’s 
differentiation. It is therefore likely that PEDF supports the maintenance of 
neurons and may keep them in a differentiated phenotype.  
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In some cases, PEDF seemed to stain the nucleolus of neurons. 
Previously, immunohistochemical data have shown that PEDF appears to be 
located not only in the cytoplasmic region, but also in the perinuclear region of rat 
neurons (Bilak et al., 1999) and is taken up and transported retrogradely by 
injured motor axons (Houenou et al., 1999).  Furthermore, PEDF was observed 
in the nucleus of postnatal P8 rat motor neurons after incubation of motor 
neurons slices with fluorescein labeled PEDF. Incubation of isolated embryonic 
motor neurons with PEDF however did not label the nucleus, although PEDF 
increased their survival (Bilak et al., 2002). Also, PEDF has been described to be 
localized in association with the nucleus of RPE cells (Tombran-Tink et al., 1995) 
which was also observed in this study (see Fig. IV.2.4). The presented data 
therefore suggest that PEDF might be also taken up by other neuronal 
phenotypes than motor neurons and possibly function as a transcription factor in 
the nucleus. 
 
PEDF has been shown to play a potential role in degenerative diseases of 
the CNS. For instance, PEDF has been found elevated in the CSF of patients 
with amyotrophic lateral sclerosis where it has been suggested to have an 
autoprotective function (Kuncl et al., 2002). Furthermore, a preliminary study has 
found increased immunoreactivity of cortical neurons and astrocytes in the CNS 
of patients with Alzheimer’s disease, where it has been proposed to function as a 
compensation mechanism to fight against neuronal cell injury (Yamagishi et al., 
2004). It has been suggested that PEDF may preferentially act on “abnormal” or 
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“sick” cells (Bilak et al., 2002). The finding that PEDF induces the differentiation 
of tumor cells in vitro and in vivo (Crawford et al., 2001), and has neuroprotective 
effects on various neuronal phenotypes would be in line with this idea.  
 
The labeling of endothelial cells for PEDF suggests that PEDF probably 
also has antiangiogenic function in the brain as has been shown in other organs 
before. This idea is supported by the finding that the loss of PEDF gene 
expression does not only correlate with the degree of glioma progression in the 
brain and in prostate cancer (Guan et al., 2003; Halin et al., 2004), but that PEDF 
expression also inversely correlates with the degree of vascularisation (Halin et 
al., 2004; Uehara et al., 2004). Consequently, PEDF overexpression has been 
shown to cause the inhibition of tumor growth by suppressing tumor 
angiogenesis and induction of apoptosis of tumor cells in the brain and other 
tissues (Matsumoto et al., 2004; Guan et al 2004; Abe et al., 2004; Wang et al., 
2003; Doll et al., 2003).  Thus, PEDF appears to have a dual effect on tumors by 
either inducing their differentiation or apoptosis and by suppressing tumor 
angiogenesis.  
 
Furthermore, there is evidence that PEDF may function as an 
antivasopermeability factor that counteracts the effects of VEGF (Liu et al., 
2004). Since PEDF labeled all vessels in the brain and colocalized with the blood 
brain barrier marker Glut1, it would be interesting to investigate if PEDF 
expression of endothelial cells decreases in conditions with vascular leakage and 
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breakdown of the blood brain barrier. In fact, the permeability modulating effect of 
PEDF during development and pathological conditions is currently being 
investigated in our laboratory.  
 
In summary, the wide distribution of PEDF in neuronal and endothelial 
cells in the brain is in line with the hypothesis that PEDF may have important 
functions as a neurotrophic and/or neuroprotective factor, as well as a modulator 
of vessel growth. Further research will be needed in order to find out which 
additional cells types were immunolabeled for PEDF that were not of neuronal, 
astrocytic or oligodendrocytic origin. These unidentified cells, together with the 
localization of PEDF-positive neurons in many specific –so far not described- 
areas of the adult brain, including neurogenic regions, open the possibility to find 




V.3. Do Cerebellar granule cell cultures produce PEDF in vitro? 
It has been previously shown that cerebellar granule neurons (CGN) respond 
to PEDF (Araki et al., 1998; Yabe at al, 2001) and appear to have a PEDF 
binding protein (Alberdi et al., 1999). Interestingly, the cerebellum was one of the 
two brain regions of the adult human brain that did not show a transcript for 
PEDF (Tombran-Tink et al., 1996), suggesting that in this brain region PEDF may 
not be produced. Since the present study could not clearly determine whether 
CGN’s were PEDF immunopositive, and in order to test if CGN’s might produce 
PEDF, CGN cultures from 7 day old Wistar rat pubs were established, stained for 
PEDF and their conditioned media tested for PEDF.  
 
Results:  
CGN cultures were established as described in chapter III, grown for 5 days 
in culture and then homogenized or stained for PEDF. Figure V.3.1 shows a clear 
PEDF signal in the conditioned medium of CGN cultures, while the control 
medium is negative for PEDF, indicating that CGN cultures produce PEDF. 
Although the same amount of protein was loaded on the Western gel as for eye 
and brain homogenates as indicated by the strong signal for ß-actin, no signal for 
PEDF could be detected in CGN cell lysates.  
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Fig. V.3.1) PEDF production of cerebellar granule neuron cultures.  
50 µg of a cell lysate of a CGN culture (lane 2) that was grown for 5 days in 
culture and 35 µl of its conditioned medium (CM, lane 3) were separated by 
SDS/Page and stained for PEDF. PEDF (lane 1) and growth medium served as 
control (CM-control, lane 4). As an internal control for loading, Western blots 
were stripped and incubated with b-actin which was detected at about 37 kDa.  
 
Contrary to immunohistochemical stainings of the cerebellum of the adult rat 
brain, in culture CGN’s showed a strong reaction to PEDF (Fig. V.3.2). IgG 
control stainings were completely negative indicating the specificity of the 
staining. Although cultures also contained astrocytes, they did not stain for PEDF 
(data not shown) and only CGN’s and a few fibroblasts stained for PEDF. CGN’s 
were identified by their typical appearance and small round soma, as well as by 
double labeling with NeuN (data not shown). 
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Fig. V.3.2 Fluorescent staining of a CGN culture with PEDF antibody (A). The 
appropriate IgG control shows completely negative staining (C). A nuclear 
staining with Hoechst of the same area as shown in (A) shows that the majority 
of cells in culture were CGN’s (B). CGN’s were identified by their typical small 
round appearance. The data shows that nearly all cells in culture stained with 




Western results support the hypothesis that CGN cultures not only 
produce, but also secrete PEDF, since PEDF could be detected in the 
conditioned medium while the control medium was negative for PEDF. The 
finding that cell lysates did not contain measurable amounts of PEDF, although a 
high amount of protein was loaded on the gel, indicates that PEDF does not 
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accumulate in these cells to a large extend.  Similarly, PEDF could only be 
localized in some cells after inhibition of its secretion (Kozaki et al., 1998). 
It is not sure if PEDF in CGN cultures might have been also derived from a 
small amount of fibroblasts in culture, since it has been shown that fibroblasts are 
able to produce PEDF (Pignolo et al., 1993; Palmieri et al., 1999). In order to 
answer this question in situ hybridization would have to be performed, or cell 
cultures produced that are 100% free of fibroblasts.  
However, PEDF strongly labeled CGN’s in vitro, suggesting that CGN’s 
might possibly produce PEDF. This idea is supported by the fact that PEDF 
mRNA is expressed in nearly all cells of the retina (Behling et al., 2002; 
Karakousis et al., 2001), as well as motor neurons (Bilak et al., 1999) which also 
immunohistochemically stain for PEDF. Alternatively, CGN’s might only bind 
PEDF. This hypothesis is supported by the finding that contrary to most other 
brain regions the PEDF transcript could not be detected in the human 
cerebellum, suggesting that PEDF may not be produced in this part of the brain 
(Tombran-Tink et al., 1996) and only bind to CGN’s. PEDF would then have to be 
transported into the cerebellum via the CSF or other cellular connections in order 
to affect CGN function. The lack of PEDF gene expression in the cerebellum, and 
therefore a potential low PEDF content in this part of the brain, might explain why 
it was not possible to determine for sure whether CGN’s stained for PEDF in 
brain slices. Alternatively, the PEDF production in the cerebellum under 
physiological conditions might be too low in order to be visualized by 
immunohistochemical means. A low PEDF content in the cerebellum would also 
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explain why CGN’s in culture were strongly labeled for PEDF while CGN’s in 
brain slices were only weakly stained for PEDF or not at all.  
 
In summary, although it could not be determined for sure whether CGN’s 
produce PEDF themselves, the data indicate that CGN’s in vitro and in brain 
slices bind PEDF. The low PEDF signal in brain slices is likely due to the 




V.4. PEDF immunostaining in the rat brain during postnatal brain 
development.  
PEDF has been shown to have different effects on mature versus 
immature neurons (Taniwaki et al., 1997; Araki et al., 1998; Bilak et al., 1999; 
Houenou et al., 1999) and has been found to be elevated in brain diseases like 
amyotrophic lateral sclerosis and Alzheimer’s disease (Kuncl et al., 2002; 
Yamagishi et al., 2004). To test if the same staining pattern of PEDF could be 
observed at early postnatal ages and very old ages compared to the young adult 
brain, brains from Long Evans rats were stained for PEDF and analyzed at birth, 
2 weeks, 1 month, 3 and 17 months of age.   
 
Results: 
At birth, only vessels intensely stained for PEDF, as indicated by double 
labeling with Glut-1, although there was a relatively strong general background of 
the tissue (Fig. V.4.1 and V.4.2). Although staining intensities were not 
measured, it was obvious that the PEDF labeling of vessels was the strongest at 
the earliest age tested and vessel staining significantly decreased already by two 
weeks of age after which it did not appear to change any more (Fig. V.4.2).  
Neuronal labeling of PEDF only started to appear around one month of age, as 
determined by double labeling with NeuN (data not shown), typical appearance 
of stained structures and location in the brain (Fig. V.4.2 and Fig. V.4.3). Neurons 
still showed prominent staining at old age, although only at this age some 
unspecific granular staining could be observed as well (Fig. V.4.2F and V.4.3F). 
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In general, neurons were labeled stronger in adulthood than at young age and 






Fig. V.4.1) Fluorescent double labeling of a Long Evans brain at birth with PEDF 
(A) and Glut-1 antibody (B). Images were super imposed and show that all PEDF 
positively stained structures also stained for the vessel marker Glut-1 (C), 
indicating that at birth PEDF can be only localized in vessels.  
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Fig. V.4.2) Fluorescent staining of the cortex of Long Evans brains with PEDF 
antibody at birth (A), 2 weeks (B), 1 month (C), 3 months (D) and 17 months of 
age (E). (F) shows the same image in (E) with a green filter, indicating that there 
is some unspecific staining that is granular in appearance (arrow heads) and only 
appeared at 17 months of age. The figure shows that typical labeling of neuronal 
cells with PEDF antibody (arrows) only started to appear at 1 month of age and 
lasted until high age.  
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Fig. V.4.3) Fluorescent staining of the dentate gyrus of Long Evans brains with 
PEDF antibody at birth (A), 2 weeks (B), 1 month (C), 3 months (D) and 17 
months of age (E). The IgG control of a 17 month old brain (F) indicates that 
there is some unspecific staining that is granular in appearance (arrow heads) 
and only appeared at this age. The figure shows that typical labeling of neuronal 
cells with PEDF antibody (arrows) only started to appear at 1 month of age and 




PEDF immunohistochemistry of endothelial cells was especially strong at 
birth and decreased in staining intensity already by two weeks of age, suggesting 
PEDF’s involvement in early brain development and especially in vessel 
development. The clear labeling of endothelial cells at a time when vessels are 
still growing suggests that PEDF might not only function as an antiangiogenic 
agent in the brain at this developmental stage. This idea is supported by a study 
that shows that PEDF can in fact have opposite effects on endothelial cells of 
different phenotype (Hutchings et al., 2002). In this study, PEDF stimulated 
endothelial cell growth if endothelial cells were previously stimulated with VEGF. 
Another hypothesis that might explain the strong vessel staining early in 
development would be that PEDF might only play a role in later stages of vessel 
formation after the sprouting endothelial cells roll up to form tubes and blood 
circulation begins (Peterson et al., 2003). PEDF might then function as an 
angiogenesis terminator. It has been also shown in various eye diseases that 
PEDF induces apoptosis only of activated endothelial cells that participate in the 
process of neovascularisation, but not of endothelial cells of established vessels, 
furthermore indicating that not all endothelial cells seem to respond to PEDF in 
the same way.  
In addition to modulating the growth of endothelial cells, in the eye PEDF 
has been shown to have antivasopermeability function and reduces the VEGF-
induced vascular permeability (Liu et al., 2004). Thus, PEDF could be an 
important regulator of the permeability of the blood brain barrier as well. It is 
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possible that PEDF confers its different effects on endothelial cells by different 
receptors on the same cell, or by different posttranslational modifications of the 
protein that affect its function. For instance, the same non-phosphorylated 44mer 
(amino acid 78-121) that confers the neurotrophic activity of PEDF also 
possesses permeability modulating activity for endothelial cells. It furthermore 
has been shown that the antivasopermeability effect depends on a subset or all 
four amino acids at position 101, 103, 112 and 115. Interestingly, PEDF in the 
plasma is a phosphoprotein and Ser114 is the main phosphorylation site of the 
extracellular located protein kinase CK2 which enhances the antiangiogenic 
activity of PEDF (Maik-Rachline et al., 2004). Thus, it could be possible that the 
phosphorylation state of the protein may not only influence the antiangiogenic 
and neurotrophic function of the protein, but also its antivasopermeability effect 
due to the close vicinity of amino acids that confer the anti-angiogenic and anti-
vasopermeability function to the protein. Another possibility is that PEDF might 
have different effects on endothelial cells during different stages of development. 
Further knowledge of the PEDF receptor(s) and the effects of the different 
posttranslational modifications of PEDF will be needed in order to understand 
how PEDF exerts its different functions on endothelial cells under normal 
physiological conditions.  
 
For neuronal cells, the temporal pattern of the PEDF staining intensity was 
exactly the opposite compared to endothelial cells. At birth and young postnatal 
age, virtually no or very little PEDF labeling of neuronal cells could be detected. 
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With increasing maturity of the brain, however, PEDF immunoreactive neurons 
increased in staining intensity. Due to the fast secretion of PEDF from the cell, it 
is probable that immunohistochemical staining of cells for PEDF reflects bound or 
internalized PEDF rather than intracellularly produced PEDF, so that the 
increased staining could possibly reflect an upregulation of a PEDF receptor. 
However, PEDF has been shown to affect many different embryonic neurons. 
Thus far, there are no indications why PEDF staining of neurons only appeared 
between 2 and 4 weeks after birth. Similarly to the brain, at birth no PEDF 
staining could be detected in the undifferentiated neuroblastic cell layer of the 
retina while the differentiated RGC layer was labeled for PEDF, suggesting that 
only fully mature and differentiated cells may be labeled for PEDF. In line with 
this idea is the report that no PEDF signal could be observed in the nucleus of 
isolated embryonic cultures upon incubation with labeled PEDF, while in 
postnatal day 8 slice cultures of motor neurons PEDF could be localized in the 
nucleus (Bilak et al., 2002). Bilak and colleges have therefore suggested that 
PEDF might have different signaling pathways at different developmental stages 
(such as autocrine versus paracrine).  
In fact, it has been shown that PEDF can have different effects on the 
same cell type depending on its state of maturity. Thus, PEDF protects 
developing but not mature hippocampal neurons against glutamate-induced 
toxicity (DeCoster et al., 1999). PEDF also protects immature CGN’s, but not 
mature CGN’s against natural apoptotic cell death (Araki et al., 1998), and 
protects mature CGN’s from glutamate-induced toxicity (Yabe at al, 2001). It 
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furthermore has been shown that the different effects of PEDF on mature versus 
immature CGN’s appear to be caused by a differential activation of genes. For 
instance, PEDF led to a long lasting induction of genes for nerve growth factor, 
brain derived neurotrophic factor and glial cell derived neurotrophic factor in 
mature neurons, while immature neurons upregulated anti-apoptotic genes for 
Bcl-2, Bcl-x and manganese superoxide dismutase upon PEDF exposure (Yabe 
at al, 2001). Similarly, PEDF was shown to activate proinflammatory genes in 
neonatal astrocytes, but not in adult astrocytes (Yabe et al., 2005). Thus, the 
state of differentiation appears to control the intracellular cascades and gene 
expression that are activated by PEDF.  
 
In summary, the data of this work are in support of the hypothesis that 
PEDF plays an important role during early development of the brain and in 
particular in vessel growth and maintenance. The stronger immunohistochemical 
staining of neurons for PEDF with increasing maturity of the brain suggests that 
the function or signaling pathway of PEDF in the brain may change with age. The 
findings of this study are also in agreement with previously published reports 
which suggest that PEDF may affect immature neurons by inducing their 
differentiation and by preventing their natural apoptotic death, while promoting 
protection against acute toxicity and slow glutamate-mediated neurodegeneration 




V.5. Overall PEDF content during brain development. 
There is evidence that PEDF protects immature, as well as some mature 
neurons against various types of cell death. However, PEDF could only be 
localized in neurons later in postnatal life. Contrary to that, staining of vessels 
was the strongest just after birth. Therefore, the overall PEDF content was 
measured during late embryonic brain development until old postnatal age in 
order to determine the overall PEDF content during brain development. For that 
purpose, brains of Long Evans and Wistar rats were collected at various time 
points between embryonic day 15 and 17 months of age and their PEDF content 
measured by Western blot analysis.  
 
Results: 
Western blot results indicate that there was no overall difference in PEDF 
content of brains between Long Evans and Wistar rats as determined by a 
Kruskal Wallis test (P=0.355, n=119; data not shown), indicating that there are no 
strain specific differences in the PEDF content of the brain. Therefore results 
were combined.  
As can be seen in figure V. 5.1, the PEDF content of the entire brain was 
the highest during embryogenesis with 402±4.2 pg/µg protein at E15, and 
decreased already by about 43% at birth. With increasing postnatal age, the 
PEDF content decreased even further, but not to the same degree as during 
embryogenesis and reached a low level of 105.4±1.9 pg/µg protein at 3 months 
of age. A Spearman rank correlation test showed that after 3 months there was 
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no significant change any more in the PEDF content with age (n=30, r=-0.247; 
P=0.189). Overall however, a Spearman rank correlation indicated that the PEDF 
content of rat brains significantly decreased with increasing age (n=120,           
r=-0.899; P<0.000).  
 
 
Fig. V. 5.1) PEDF content of rats brains from E15 until high age.  
50 µg of complete male Long Evans and Wistar brain homogenates between E15 
and 22 months of age were analyzed by Western blot analysis. PEDF was 
normalized to the average actin signal and then compared to a standard curve of 
PEDF (15-60 ng, not shown). Data are shown as mean ± SEM.  A Spearman 
rank test showed that overall there was a significant decrease of PEDF with 
increasing age (n=119, r=-0.927, P<0.000). After 3 months of age, however, 
there was no correlation between the PEDF content of brains and age any more 
(Spearman rank, n=30, r=-0.247, P=0.189). 
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In order to find out whether the measured PEDF content of the brain was 
mainly derived from cells in the brain or from blood, the PEDF content of serum 
from animals between birth and 17 months was tested. As can be seen in figure 
V.5.2, the PEDF content in the serum significantly increased between birth and 2 
months (P<0.002, n=20) from 2.96±0.31 µg/ml to 9.2±0.43 µg/ml. Serum levels 
stayed the same between 2 and 3 months (P=0.762, n=10), but significantly 
decreased afterwards to levels between 5.89±0.4 and 6.99±0.53 µg/ml (3 versus 
8 months: P=0.029, n=8). There was no significant change in PEDF serum levels 
after 8 months of age (P= 0.257, n=10).  
Fig. V.5.2) The PEDF content of blood serum from birth until old age.  
0.5 µl of blood serum from Long Evans rats between P0 and 17 months of age 
was separated by SDS/Page, stained for PEDF and compared to a standard 
curve of PEDF (1-10 ng, not shown). Data are shown as mean ± SEM. A Kruskal 
Wallis test showed that overall there was a significant change of PEDF over age 
(P<0.000, n=34) and a Mann-Whitney-U test showed that there was a significant 
difference in the PEDF levels between P0 and P14 (P=0.038, n=10), 1 and 2 




Peterson and colleges (2003) have previously reported the adult human 
PEDF plasma concentration to be approximately 5 µg/ml which is similar to rat 
serum levels of this study which ranged from 3-9.2 µg/ml. Contrary to PEDF 
levels in the brain which decreased with increasing age, the serum 
concentrations of PEDF more than tripled between birth and young adulthood, 
but significantly decreased again by 34-22% at 8-17 months compared to levels 
at 3 months.  
The mean capillary distance can be considered as an indicator for 
neuronal activity in the pericapillary environment and is an indicator for vessel 
growth (Jucker et al., 1990). It has been shown that in the rat visual cortex the 
capillary volume and density increases before birth and between 10 and 20 days 
after birth, with no subsequent change thereafter (Keep and Jones, 1990). 
Similarly, Tieman and colleges (2004) have shown that there is an increase in 
the blood vessel density between 1 and 6 weeks of age in the cat’s visual cortex. 
At old age however, the capillary density decreases again in various areas of the 
brain (Jucker et al., 1990; Lynch et al 1999). There are also indications that 
PEDF in the blood functions as an antiangiogenic factor (Maik-Rachline et al., 
2004). This would be in agreement with data of this study that show that PEDF in 
the serum is low early in postnatal life, at a time when brain development and 
vessel growth are still ongoing, and high during adulthood when normally there is 
no change in vascular density.  
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The decrease of PEDF in the serum at old age, at a time when the 
capillary density also decreases, suggests that PEDF may be required for vessel 
maintenance. Likewise, the plasma levels of insulin-like growth factor 1, which 
has an important role in vascular maintenance and remodeling, have been 
shown to be correlated with the decreasing vascular density with increasing age 
(Sonntag et al., 1997).  
 
In the brain, the most dramatic decrease of the total PEDF content 
occurred between embryonic day 15 and 3 months of age. Afterwards, there was 
no significant change any more in the PEDF content of the brain. In comparison 
to that, vessel volume and density increase until about 3 weeks in the rat’s visual 
cortex and PEDF serum concentrations reach their maximum at 8 weeks after 
birth. Therefore, one has to conclude that the PEDF production in brain tissue 
itself is the highest during embryogenesis and decreases already early in 
postnatal life. Because PEDF levels in complete brain homogenates remained 
fairly constant after 3 months of age, but PEDF serum concentrations decreased 
and potentially also the vessel density as well, it may be possible that PEDF 
production increases slightly again in old brain tissue compared to young adult 
brain. This idea is supported by the relatively strong staining of neurons as well 
as endothelial cells at old age. Furthermore, since the PEDF content was the 
highest at a time when practically only endothelial cells intensely stained for 
PEDF, it could be assumed that at least early during brain development the 
majority of the PEDF in the brain might be derived from endothelial cells and not 
 157
from neurons. However, further investigations such as in situ hybridization will be 
needed in order to verify these hypotheses.  
 
PEDF is also known as early population doubling level complementary 
DNA-1 or EPC-1 and in RPE cells and fibroblasts PEDF production has been 
shown to be decreased with the exhaustion of the cell cycle in replicative 
senescence (Pignolo et al., 2003; Tombran-Tink et al., 1995). The protein has 
also been suggested to play a role in the entry of early passage cells into a Go 
state or in the maintenance of such a state, since low PEDF levels increase the 
number of cells entering DNA synthesis (Pignolo et al., 2003). PEDF may thus 
function as a negative controller of the cell cycle and as a differentiation factor, 
as has been shown previously for motor neurons and retinoblastoma cells 
(Houenou et al., 1999; Tombran-Tink and Johnson, 1989; Tombran-Tink et al., 
1991). This would be in line with the finding of this study that PEDF levels 
decreased rapidly during embryogenesis and early postnatal life once cells are 
differentiated. Preliminary unpublished in vitro and in vivo data of our laboratory 
have also shown that PEDF inhibits the VEGF-induced replication of stem cells in 
the subventricular zone, furthermore supporting the idea of PEDF as a negative 
controller of the cell cycle.  
Previously cited reports have shown that in immature neurons PEDF 
appears to have mainly survival and differentiating effects, while it mainly 
protects mature neurons against various kinds of insults. A high concentration of 
PEDF in the brain during embryogenesis and decreasing levels of PEDF with 
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age would be in accordance with this idea and suggest that the main function of 
PEDF may be during embryogenesis and early postnatal development of the 
brain. In support of this idea is the suggestion of Kozaki and colleges (1998) that 
PEDF may play an important role in organogenesis and morphogenesis due to 
the location of PEDF in relation to the formation of bone, cartilage, teeth and 
basement membrane in the mouse embryo. 
 
In conclusion, the finding that PEDF levels were the highest at E15 and 
decreased fast during embryogenesis suggests an important role of PEDF during 
early brain development and are in line with the idea of PEDF as a differentiation 
factor. The fact that PEDF levels in the entire brain remained constant in 
adulthood, although PEDF serum levels decreased, suggests that PEDF may 
have also significant functions in the brain during adulthood. The finding of this 
work that serum PEDF concentrations changed with age, and that blood cells are 
able to express the PEDF gene could possibly help in the early detection of 
diseases in which serum PEDF might play a role.  
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V.6. Final conclusions of chapter V. 
▬ The high PEDF content in the brain during embryogenesis and early postnatal 
age, and the strong labeling of vessels at young age suggest that PEDF may 
play an important role early during brain development and in particular in 
vessel growth and their maintenance.  
▬ The low PEDF concentrations in the blood at a time when vessel growth 
continues in the brain is in support of the idea that PEDF is an antiangiogenic 
agent in the blood. 
▬ The labeling of neurons in many different brain regions until old age and the 
low, but constant PEDF levels in the entire brain from 3 months on indicate 
that PEDF may have also important functions in the brain even at high age 
and support the idea of PEDF as a neurotrophic and neuroprotective factor.  
▬ The strong immunoreaction of cells in the ventricular zone and dentate gyrus 
suggests that PEDF may be even involved in neurogenesis. This hypothesis 
is supported by preliminary in vitro and in vivo data of our laboratory that 
suggest that PEDF modulates stem cell replication. 
 
In conclusion, the data of this study are in line with the hypothesis that 
during postnatal development of the brain PEDF functions as a neurotrophin, 
differentiating and/or neuroprotective factor, as well as an important regulator 




VI. Differences in posttranslational glycosylation of PEDF are tissue 
specific and developmentally regulated. 
 
VI.1. Introduction:  
There is only one known gene for PEDF that is rather conserved among 
different species (Singh et al., 1998; Tombran-Tink et al., 1996). The gene 
contains 8 exons and 7 introns and there are no alternative splice forms known. 
PEDF is a monomeric glycoprotein with a globular structure that has one 
protease-sensitive exposed loop. Since there is no known protease target for 
inhibition, no conformational change and no impairment of its neurotrophic 
function upon cleavage of the protease-sensitive loop, PEDF belongs to the non-
inhibitory serpins (Becerra et al., 1995).  
The human 418 amino acid large protein is secreted from the cell upon 
production and has been reported to have a size of 46-50 kDa. It has been 
shown that residue position 78-121 confers neurotrophic function to the protein 
(Alberdi et al., 1999; Bilak et al., 2002) and has antivasopermeability function (Liu 
et al., 2004), while the  phosphorylation of PEDF at Ser 24 and mainly 114 is 
related to its angiogenic activity (Maik-Rachline et al., 2004).  
 Although there are indications that the effects of PEDF as angiogenic 
inhibitor and neuroprotective agent may be mediated by different types of 
receptors of different size (Alberdi et al., 1999; Yamagishi et al., 2002), until now 
no receptor has been characterized in detail. Apart from phosphorylation at three 
different amino acids, other posttranslational modifications of the PEDF protein 
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have been reported, such as deamination of the N-terminal and N-linked 
glycosylation (Peterson et al., 2003; see also Fig. I.2.2, page 6) which might also 
have an effect on the function of PEDF. The N-terminal of the protein can be 
deaminated by a posttranslational modification of glutamine to pyroglutamate 
(pGlu) and is then sensitive to Edman degradation or not sensitive to Edman 
degradation if only the preceding asparagine is present (Peterson et al., 2003). 
Although the function of this modification is not known, it has been suggested 
that removal of pGlu may modify the higher order structure of PEDF (Peterson et 
al., 2003) and therefore possibly also its function.  This is insofar interesting as 
PEDF protein from bovine interphotoreceptor matrix is unblocked (Wu et al., 
1995) and PEDF in bovine vitreous and blood is blocked to Edman degradation 
(Wu and Becerra, 1996; Petersen at al, 2003).  
 Most proteins are subject to posttranslational modifications of which 
glycosylation is the most common form. Glycosylations perform critical biological 
functions such as protein sorting, immune recognition, receptor binding, 
inflammation, pathogenicity and many other processes. The majority of proteins 
that are secreted into the extracellular space are glycoproteins, while very few 
proteins in the cytosol are glycosylated. There are two major classes of 
oligosaccharides (glycans) that are attached to proteins in the endoplasmatic 
reticulum and/or the Golgi apparatus. N-linked glycans are attached to the amide 
side chain of Asn which form part of the amino acid triplet AsnXaaSer/Tre, where 
Xaa is any amino acid except Pro. O-linked glycans are added to Ser or Thr 
residues. The terminal residues on these carbohydrate chains are commonly 
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sialic acids which affect the charge of the protein. The diversity of 
oligosaccharide structures attached to proteins often results in heterogeneity of 
the mass and charge of proteins. 
PEDF has one potential N-linked glycosylation site at position Asn 266 
and PEDF in the blood has been reported to carry a disialylated biantennary 
complex type glycan with or without core fucosilation (Petersen et al., 2003; see 
Fig I.2.2, page 6). Di- monosialylated and asialylated structures without core 
fucosilation have also been found, so that the calculated molecular mass of 
PEDF can range from 4197-4926 Da and deglycosylation of blood PEDF with 
PNGaseF has been previously reported to reduce the molecular weight by 2 kDa 
as analyzed by Western Blot analysis (Petersen et al., 2003).  
To investigate whether PEDF may be differentially glycosylated, PEDF 
was enzymatically digested with N-Glycosidase F (PNGaseF) or sialidase 
(neuraminidase) and analyzed by Western blotting.  PNGaseF removes virtually 
all N-linked oligosaccharides from glycoproteins that do not contain a fucose, 
while sialidase removes all sialic acids groups from the oligosaccharide while 
leaving the glycan chain attached to the protein. To detect any change in 
molecular mass, the migration pattern of protein samples was analyzed by 
Western blotting. During Western blot analysis, denaturated proteins migrate in 
an electrical field and are separated on a SDS/page gel by their different size. 
The height of the stained band thus corresponds to the molecular weight of the 
protein and the number of bands indicates differences in the posttranslational 
modification of the protein that change the protein’s mass. Since with this method 
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it is hard to calculate the absolute weight of the protein, the molecular mass of 
PEDF was estimated for easier reading of this chapter. 
 
The chapter is divided in three parts in order to address the following 
questions. First, to test whether age affects the glycosylation status of PEDF, the 
glycosylation status of PEDF of eye and brain samples of various postnatal ages 
was investigated. Second, in order to investigate whether the molecular mass of 
PEDF and thus its posttranslational modifications are tissue specific, several cell 
cultures were established and their cell lysates and conditioned media tested for 
PEDF in order to furthermore compare secreted and intracellular PEDF. Third, 
cell lysates and conditioned media of differentiated and undifferentiated retinal 
pigment epithelial cells were tested for PEDF in order to investigate whether the 
cell’s differentiation status affects the glycosylation status of PEDF. 
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VI.2 Results:  
VI.2.1 Is the glycosylation status of PEDF related to the age of the 
organism?  
During postnatal development of the eye, the number and molecular 
weight of PEDF bands changed (Fig. VI.1), indicating a different posttranslational 
modification of the protein at different developmental ages. Just after birth, PEDF 
was displayed as three bands of very close molecular weight. However, the 
middle sized protein of about 47kDa was the most prominent one at this age. 
Homogenates from young adult eyes clearly contained two prominent PEDF 
forms of 46 and 48 kDa that were equally presented.  At very old age, only the 48 
kDa band of PEDF could be consistently detected. When eye homogenates of 
these developmental ages were deglycosylated with PNGaseF, PEDF of all 
samples was reduced to one major PEDF form of about 44 kDa and an additional 
lower band that was rather faint, indicating that PEDF of all eye samples was N- 
glycosylated.  
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Fig. VI.1) Changes in posttranslational N-linked glycosylation of PEDF during 
postnatal development of the eye.  
50 µg protein of eye homogenates from Long Evans rats at P0 (lane 2), 2 months 
(lane 4) and 21 months (lane 6) were deglycosylated with PNGaseF, separated 
by SDS/Page and stained with PEDF antibody. Human recombinant PEDF 
served as control (lane 8). Deglycosylated proteins are always shown on the left 
compared to native proteins.  
 
Similar to PEDF from complete eye homogenates, PEDF derived from 
brain homogenates of different ages also showed differences in the size and 
number of PEDF bands as revealed by Western blot analysis (Fig VI.3a). At birth, 
PEDF was displayed as one major band of about 46 kDa, while PEDF from adult 
brains was always detected as a double band of 46 and 48 kDa. Similar to old 
eye homogenates, only the 48 kDa band could be detected in very old brain 
homogenates. Digestion of a P8 brain homogenate with sialidase reduced PEDF 
to one major molecular weight form of about 44 kDa and a smaller faint band (Fig 
VI.3b), indicating that PEDF in the brain is a glycoprotein as well. Furthermore, 
PEDF of the digested brain homogenate appeared to migrate at similar height as 
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PEDF from the digested eye homogenate at 2 months of age. The data provide 
evidence that in the eye and the brain PEDF is a glycoprotein and that the 
degree of glycosylation is age dependent.  
 
 
Fig. VI. 3) PEDF in the brain is a glycoprotein. 
A) 50 µg from rat brain homogenates from animals at P0 (lane 2), 8 months 
(lane 3) and 22 months (lane 4) were separated by SDS/Page and stained 
with PEDF antibody. PEDF at P0 migrated as one major band, while PEDF at 
8 months migrated as a double band of larger size. At 22 months, only one 
band of higher molecular size was detected. Lane 1 shows a positive control 
of recombinant human PEDF. 
B) 50 µg of a homogenate from a 2 month old Long Evans eye (lane 2) and an 8 
day old rat brain (lane 4) were enzymatically treated with sialidase (lane 3 and 
5), separated by SDS/Page and stained with PEDF antibody. Human 
recombinant PEDF served as positive control (lane 1). PEDF from both 
sources were decreased in molecular weight upon cleavage of sialic acid 
residues. 
 
The following table gives an overview of the effect of deglycosylation on 
the molecular weight of PEDF of eye and brain homogenates (table VI.1). 
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Tissue age            native PEDF  deglycosylated PEDF
number molecular number molecular 
of bands size [kDa] of bands size [kDa]
Eye postnatal 1 main band 47 1 main band 44
adult 2 46, 48 1 main band 44
old 1 48 1 main band 44
Brain postnatal 1 46 n/a
adult 2 46, 48 n/a
old 1 48 n/a
 
 
Table VI.1. Estimated molecular weight and number of native and deglycosylated 
PEDF bands of eye and brain tissue during postnatal development as shown in 
Western blots.  
 
VI.2.2 Does the molecular mass and the glycosylation status of intracellular 
and secreted PEDF from different cell types change? 
PEDF derived from tissue homogenates contains both the secreted and 
the intracellular protein, as well as PEDF derived from blood serum. To find out 
whether there are any differences in protein size between the intra- and 
extracellular form of the protein, cell cultures were established of rat retinal 
pigment epithelial cells, rat fibroblasts, rat CGN’s and human hepatocytes. 
Intracellular PEDF derived from RPE cell lysates was detected as a double band 
of about 46 and 44 kDa (Fig. VI. 2a). The secreted 46 kDa protein in the 
conditioned medium was however detected as a single band.  
As for RPE cultures, PEDF from the conditioned medium of CGN cultures 
contained only one homogeneous form of PEDF as indicated by the existence of 
one prominent band of about 46 kDa (see Fig V.3.1). However, intracellular 
PEDF from CGN culture cell lysates could not be detected, indicating that the 
intracellular amount of PEDF in CGN’s was not high enough in order to be 
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detected by Western blot analysis. Comparison of PEDF from conditioned media 
of CGN’s, RPE- and fibroblast cultures showed that all conditioned media 
contained a single size protein of 46 kDa (Fig VI.4). Furthermore, RPE and 
fibroblast cell lysates both displayed a double band of about 44 and 46 kDa, 
indicating a large amount of intracellular PEDF in order to be detected by 
Western blot analysis. The data of these experiments show that the molecular 
mass of PEDF and therefore also its posttranslational modification differs 
between intracellular and extracellular derived PEDF of three different rat cell 
types.  
 






Fig. VI.4) Intracellular and secreted PEDF from various types of cell cultures. 
25 µl of conditioned media (CM) from human hepatocytes (lane 5), 
undifferentiated rat RPE cells (lane 6), rat fibroblasts (lane 7) and rat CGN’s (lane 
8) were separated by SDS/Page and stained with PEDF antibody. Equal 
amounts of growth medium for fibroblasts (lane 2), RPE cells (lane 3) and CGN’s 
(lane 4) served as controls and showed no or neglectable amounts of PEDF. 
Lanes 9 to 12 show signals from cell lysates of CGN’s (90 µg), hepatocytes (200 
µg), fibroblasts (about 100 µg) and RPE cells (3.75 µg). Lane 1 shows a positive 
control of human recombinant PEDF. Except for hepatocytes, secreted PEDF 
consisted of one molecular weight form, while PEDF from fibroblast and RPE cell 
lysates migrated as a double band.  
 
 
To confirm the cell type which was used for cell lysates, cultured cells 
were stained immunohistochemically. Rat RPE cells have been previously 
described to stain for nestin under the employed culture conditions (Engelhardt et 
al., 2005) and are known to stain for PEDF. The typical morphological 
appearance and the labeling for both PEDF and nestin indicated that cultures in 
fact contained RPE cells (Fig. VI.5). Fibroblasts have been previously described 
to also produce PEDF (Pignolo et al., 1993 and 2003). Therefore, the employed 
skin fibroblasts from neonatal transgenic Sprague Dawley rats which were 
overexpressing green fluorescent protein (GFP) were immunostained for PEDF 
(Fig. VI.5). The typical appearance and staining for PEDF indicated that cultures 
contained fibroblasts. Interestingly, the nucleus of RPE cells, but not of 




Fig. VI.5) Staining of differentiated rat RPE cells (C) and green autofluorescent 
skin fibroblasts from GFP expressing transgenic rats (E) with PEDF antibody. 
RPE cells were also nestin positive (A). Appropriate IgG controls are always 
shown on the right (B, D, F) which showed no staining. The figure shows that rat 
RPE cells and skin fibroblasts are stained positively for PEDF.  
 
PEDF has been shown to be expressed in large amounts in the liver 
(Singh et al., 1998; Tombran-Tink et al., 1996). Proteins of the plasma are mainly 
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produced in the liver and PEDF exists at a physiologically relevant concentration 
in the blood (Fig. V.5.2; Peterson et al., 2003). To investigate the 
posttranslational processing of PEDF derived from this nonneuronal tissue, 
human hepatocyte culture lysates and their conditioned media were digested and 
tested for PEDF. Interestingly, the protein pattern was the opposite compared to 
that found in RPE, fibroblast and CGN cultures, in that the intracellular PEDF 
was displayed as a single band of about 42 kDa, while the secreted protein 
migrated as a double band of about 44 and 46 kDa (Fig. VI.6 and VI.7). This 
indicates that both extracellular forms are modified upon secretion of the cell, 
since both extracellular PEDF forms migrated higher than the intracellular PEDF 
of hepatocytes. Digestion of the conditioned medium of hepatocytes with 
sialidase reduced the upper 46 kDa band, indicating that the difference in protein 
size of the secreted protein was due to differences in the amount of sialic acid 
residues that are attached to the N-glycan (Fig. VI.6). Upon enzymatic 
deglycosylation of the secreted PEDF, both bands seemed to be reduced to one 
molecular weight of around 42-43 kDa, indicating that the two secreted PEDF 
forms differ in the glycan residue (Fig. VI.6). Removal of glycan chains and sialic 
acid residues from the intracellular protein had no effect on the migration pattern 
of PEDF from hepatocyte cell lysates, suggesting that intracellular PEDF is not 
N-glycosylated (Fig. VI.6). The results show that in hepatocytes the glycolysation 
status of intracellular and extracellular derived PEDF differs and that the 
posttranslational modification varies from rat fibroblast, RPE and CGN cultures.  
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Fig. VI. 6) Only the secreted PEDF protein from hepatocytes is a glycoprotein.  
20 µl conditioned medium of hepatocytes (lane 1) were either digested with 
PGNaseF (lane 2) or sialidase (lane 3), which decreased the molecular weight of 
PEDF as analyzed by Western blotting and staining with PEDF antibody. 
Treatment of 100 µg hepatocyte cell lysate (lane 5) with PGNaseF (lane 6) or 
with sialidase (lane 7) did not change the migration pattern of PEDF.  A control 
for the enzymatic digestion with sialidase (lane 4) or PGNaseF (lane 8) was 
treated the same, but without enzyme, and did not change the molecular weight 
of PEDF from conditioned medium and cell lysate, respectively.   
 
Since hepatocytes are the main source of proteins in the blood, PEDF 
from conditioned medium of heptocytes was compared to PEDF of blood serum. 
As can be seen in figure VI.7, PEDF from both sources consists of double bands 
of about 44 and 46 kDa that migrate at the same height. Furthermore, upon 
digestion with sialidase, the upper 46 kDa band of both sources became 
reduced, indicating that PEDF from both sources is partially sialylated. This 
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suggests that PEDF in the blood may be at least in part derived from 
hepatocytes, since PEDF from both sources had similar molecular weight and 
reacted in the same way to treatment with sialidase.  
               
                          
Fig. VI.7) PEDF from serum and hepatocytes are similar in molecular size and 
both are partially sialylated. 
100 µg hepatocyte cell lysate (lane 2), 20 µl conditioned medium of hepatocytes 
(lane 4) and 30 µg human serum (lane 6) were treated with sialidase (lane 3, 5 
and 7, respectively), separated by SDS/Page and stained with PEDF antibody. 
Human recombinant PEDF (lane 1) served as control. While the migration 
pattern did not change in the hepatocyte cell lysate, the upper band of the double 
band of both conditioned medium of hepatocytes and serum was reduced. 
 
The following tables give an overview of the effect of deglycosylation on 
the molecular weight of PEDF of various cell lysates (table VI.2) and their 
conditioned media (table VI.2). 




   
        Cell lysates         native PEDF deglycosylated PEDF
number molecular number molecular 
of bands size [kDa] of bands size [kDa]
CGN's 0 n/a
RPE's 2 44, 46 n/a
fibroblasts 2 44, 46 n/a
hepatocytes 1 42 1 42
       
Table VI.2. Estimated molecular weight and number of native and deglycosylated 
PEDF bands of various cell lysates as shown in Western blots.  
 
   
Conditioned medium         native PEDF deglycosylated PEDF
number molecular number molecular 
of bands size [kDa] of bands size [kDa]
CGN's 1 46 n/a
RPE's 1 46 n/a
fibroblasts 1 46 n/a
hepatocytes 2 44, 46 1 44
blood 2 44, 46 1 44
  
Table VI.3. Estimated molecular weight and number of native and deglycosylated 




VI.2.3 Is the cell’s differentiation status related to the molecular mass of      
PEDF?  
To answer this question differentiated and undifferentiated rat RPE cell 
cultures were established. Differentiation of cells was achieved by removal of 
growth factors and addition of serum (for more details, see Methods, page 32-
34). Intracellular PEDF derived from both differentiated and undifferentiated RPE 
cell lysates was detected as a double band of about 46 and 44 kDa (Fig. VI. 2a), 
suggesting that in these cells the differentiation status has no effect on the 
posttranslational processing of PEDF that influences the protein’s mass. 
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Similarly, the secreted 46 kDa protein of both conditioned media was detected as 
a single band. Treatment of undifferentiated RPE lysates with sialidase reduced 
the upper of the two bands to one 44 kDa band (Fig. VI.2b), suggesting that the 
two molecular weight forms differ in the amount of sialic acid residues. 
Deglycosylation of N-linked glycans of the undifferentiated RPE cell lysate (which 
removes the entire attached oligosaccharide) however equally reduced both 
bands to the same degree, suggesting the presence of yet another type of 
modification (Fig. VI.2b). The data of these experiments therefore suggest, that 
the differentiation status has no effect on the molecular mass of PEDF and that 







Fig. VI. 2) Differentiated and undifferentiated RPE cell cultures produce PEDF.  
A) Seven µg of cell lysates from differentiated (lane 1) and undifferentiated 
RPE cell cultures (lane 2) and 35 µl of their conditioned media (CM, lane 3 
and 4) were separated by SDS/Page and stained with PEDF antibody. 
PEDF from RPE cell lysates was detected as a double band and PEDF 
from conditioned media consisted of one band that migrated at the same 
height as human recombinant PEDF (lane 7). Differentiation medium 
containing 1% FCS (lane 5) and normal growth medium devoid of FCS 
(lane 6) were used as controls for conditioned media of differentiated and 
undifferentiated RPE cell cultures, respectively, and showed no signal.  
B) About 3.75 µg of cell lysates from undifferentiated RPE cell cultures (lane 
1) were either treated with PGNaseF (lane 2) or with sialidase (lane 3) 
over night, separated by SDS/Page and stained with PEDF antibody. 
Deglycosylated PEDF migrated as a double band of lower size compared 
to the untreated sample, while desialylated PEDF was detected as a 




VI.3 Discussion:  
VI.3.1 The degree of glycosylation of PEDF is age dependent.  
Eye homogenates of various postnatal ages contained one to three forms 
of PEDF that differed in molecular weight (46-48 kDa) as indicated by their 
different migration pattern on Western blots. However, all different molecular 
weight forms of PEDF became reduced to one prominent band of same size. 
This finding indicates that the differences of PEDF in molecular size at different 
ages are mainly due to differences in the degree of glycosylation. While all forms 
of PEDF of different developmental ages were glycosylated, the degree of 
glycosylation changed during postnatal development and increased with age. 
Further digestion with sialidase would indicate if this change is due to an 
increase in the size of the glycan chain or more likely to an addition of sialic acid 
residues. The answer to this question is insofar interesting since sialic acid 
residues change the charge of the protein to a more negative one, which might 
have an influence on the binding and the function of PEDF. This hypothesis is 
supported by the finding that binding of the neuroprotective and differentiating 
serpin protease nexin-1/glia-derived nexin to extracellular matrix components 
changes its function (Bock, 1990; Donovan et al., 1994).  
As in the eye, PEDF in brain homogenates is also a glycoprotein. Since 
PEDF from eye and brain showed the same change in migration pattern during 
postnatal development, and desialylated PEDF samples from eye and brain also 
showed a similar migration pattern, it can be assumed that in the brain 
differences in molecular size of PEDF at different ages are also likely due to 
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differences in the degree of glycosylation. This, however, will have to be verified 
by further analysis.  
Thus far the significance of the differences in glycosylation and sialylation 
patterns of PEDF during development is not known. It has been previously 
shown that the type of glycosylic linkage in the overall brain changes during 
development of the CNS and the amount of terminal sialic acid residues 
increases in the adult CNS compared to younger ages (Vallejo et al., 2000). 
Since alterations in the N-glycan pattern of proteins are known to take place in 
pathophysiological conditions, such as in inflammation and diabetes mellitus 
(Higai et al., 2003), the changes in glycosylation during postnatal development 
are likely relevant to the function of PEDF. For instance, it has been shown that 
the sialylation status of human erythropoietin affects its activity in vivo (Higuchi et 
al., 1992) and is related to the circulatory clearance rate of some proteins in the 
bloodstream (Chitlaru et al., 1998; Kronman et al., 1995). Furthermore, the 
phosphorylation status of PEDF changes its biological function (Maik-Rachline et 
al., 2004). Thus, depending on the cell’s specific glycosylation status of PEDF, as 
well as the presence of extracellular enzymes that are able to posttranslationally 
modify PEDF, such as matrix proteases and serine proteases, the function of 
PEDF may change. That implies that there can be different functional working 
forms of PEDF present at the same time and space. 
 
VI.3.2 The molecular mass differs between intracellular and secreted PEDF 
of different cell types.  
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The presence of only one 46 kDa band of PEDF in conditioned media of 
RPE, fibroblast and CGN cultures (Fig. VI.4) suggests that these cells may 
modify PEDF in the same way regarding their glycosylation status. Moreover, 
there was no difference in the gross amount and migration pattern of PEDF 
produced by differentiated and undifferentiated RPE cells under the used culture 
conditions, indicating that the differentiation status has no influence on the 
production and posttranslational modification of PEDF in RPE cells as analyzed 
by Western blot analysis. PEDF has been shown to be downregulated with 
increased passaging of the cell culture (Tombran-Tink et al., 1995). Interestingly, 
PEDF could be readily detected in passaged RPE and fibroblast culture cell 
lysates, while in primary CGN culture cell lysates it was below the detection limit 
of Western blot analysis, suggesting that in RPE cells and fibroblasts PEDF 
appears to accumulate more than in CGN’s. In addition to the 46 kDa band, RPE 
and fibroblast cells also contained a smaller 44 kDa PEDF band. 
Treatment of RPE cell lysates with sialidase indicated that the two 
molecular weight forms only differed in the degree of sialic acid residues. 
However, deglycosylation of the RPE homogenate equally reduced both bands to 
the same degree, which suggests that there must be yet another type of 
modification in which the two forms differ. Since PNGaseF only removes N-linked 
glycans, this seemingly contradiction might be explained by the presence of O-
linked glycosylations that can also carry up to three sialic acid residues. 
However, so far there is only evidence of a N-linked glycosylation in human blood 
PEDF (Peterson et al., 2003). Further digestion experiments and a better 
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resolution of the different sized proteins will be needed in order to answer this 
question.   
It is not clear, why intracellular PEDF from RPE cultures consisted of a 
double band of about 44 and 46 kDa, while the extracellular PEDF showed only 
one 46 kDa form. Deglycosylation experiments suggest that both intracellular 
PEDF forms may be glycosylated. Since sugars are usually added on secreted 
proteins as they are made, it is unlikely that the smaller intracellular PEDF 
represents an immature protein. One explanation could be that the cell takes up 
some of the secreted protein that is bound to the surface and strip off some 
sugars or amino acids during this process. This scenario is insofar possible as 
RPE cells react to PEDF (Malchiodi-Albedi et al., 1998), their nucleus stains for 
PEDF and it has been shown that PEDF is taken up by axotomized motor 
neurons where it is transported towards the nucleus (Houenou et al., 1999). 
Blockage of the uptake of proteins by inhibition of endocytosis might help to 
answer this question.  
 
VI.3.3 PEDF from blood and hepatocytes.  
The liver is a major source of PEDF production (Kozaki et al., 1998; 
Tombran-Tink et al., 1996) and the main source of serum proteins in the blood. 
Digestion analysis indicated that only the secreted PEDF of hepatocytes was 
glycosylated and partially sialylated. The finding that PEDF from serum and 
conditioned medium of hepatocytes have similar migration patterns and react the 
same way to treatment with sialidase suggests that PEDF in the serum might be 
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at least in part derived from hepatocytes, in addition to PEDF that can be 
produced by blood cells themselves (see Fig V.1.1). The finding that hepatocytes 
contained an intracellular smaller form of PEDF of about 42 kDa, whose size 
could not be modified by deglycosylation or desialylation, suggests that 
hepatocytes may produce a PEDF form that does not get secreted since 
secreted proteins are normally glycosylated. It is likely that in these cells there is 
a separate biosynthetic pathway for intracellular PEDF which would not involve 
the Golgi apparatus that normally attaches sugars to proteins. Alternatively, but 
less likely, all posttranslational modifications would have to be stripped off during 
the take up of the protein from the extracellular space. Furthermore, the protein 
pattern of hepatocyte cultures was the opposite compared to that found in RPE 
cultures regarding the number of PEDF forms in cell lysates and conditioned 
media. This suggests that PEDF derived from RPE and hepatocyte cultures may 
have different functions. This idea is supported by the finding that PEDF in the 
blood has antiangiogenic function due to phosphorylation of several amino acids 
(Maik-Rachline et al., 2004), while PEDF production by the RPE layer has 
neurotrophic and neuroprotective activity (Jablonski et al., 2000 and 2001).  
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VI.4 Final conclusions of chapter VI. 
 
In conclusion, the data of this study indicate that: 
▬ The degree of glycosylation changes with age in the eye and most likely also 
in the brain which might affect the binding and the function of PEDF.  
▬ Depending on the type of cell PEDF is produced in there are differences in     
the degree of posttranslational glycosylation.  
▬ In most cell types the molecular mass differs between intracellular and 
secreted PEDF.  
▬ The cell’s differentiation status does not influence the degree of glycosylation 
of PEDF in RPE cells.  
▬ Since PEDF forms of both hepatocytes and blood serum have the same 
molecular mass and are both partially sialylated, it is likely that PEDF in the 
blood is in part derived from hepatocytes.  
 
In summary, a better understanding of the different posttranslational 
modifications of PEDF during postnatal development by different cell types and 
their biological functions will help in the understanding how PEDF experts its 
many different effects in the entire organism which might be of benefit in future 





The data that were collected during the research for this thesis suggest that: 
▬ The prominent role of PEDF in the CNS may be during embryogenesis and 
early postnatal development since overall PEDF levels decreased with 
increasing age in both eye and brain.  
▬ This decrease of PEDF is a natural phenomenon that appeared to be 
associated with the exhaustion of the cell cycle and was independent of 
pathological conditions.   
▬ The changing glycosylation patterns of PEDF during postnatal development of 
the eye and most likely also of the brain suggest a changing function of PEDF 
in the CNS with age.  
▬ The different posttranslational modifications of PEDF from various cell types 
suggest that depending on the cell type the protein is produced in PEDF may 
have different functions.  
▬ There was no significant difference in between albino and pigmented eyes 
regarding the PEDF content of complete eyes, as well as 
immunohistochemical localization of PEDF within the retina that could be 
associated with the lack of pigmentation in Wistar rats.  
▬ The data suggest that a decrease of PEDF production within the retina -as 
indicated by a reduced staining of RPE cells and preliminary Western blot 
 184
data of retinas- in combination with overall declining PEDF levels in the eye 
might contribute to the observed retinal degeneration at old age.  
▬ The results indicate that a shift in the VEGF expressing cells within the retina, 
which causes an uncoupling of PEDF and VEGF protein expression at old 
age, might be related to pathological neovascularisation.  
▬ The data of this study therefore support the idea that declining PEDF levels in 
organs at old age could easily tip the balance between angiogenic stimulators 
and inhibitors, so that the lack of PEDF as a differentiating factor and 
angiogenic inhibitor could contribute to the increase in cancer rates in the 
elderly.  
▬ The strong expression of PEDF especially in outgrowing, but also established 
vessels of both eye and brain suggest not only an important role of PEDF 
during physiological angiogenesis early in postnatal life, but also in the 
maintenance of vessels during adulthood.  
▬ The finding that overall VEGF/PEDF ratios, as well as the expression patterns 
of VEGF and PEDF within the retina differed between pathological 
neovascularisation and vessel growth after birth, suggests that 
neovascularisation and normal occurring angiogenesis may be regulated 
differently.  
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▬ The data of this study are furthermore in agreement with the hypothesis that 
PEDF does not always act on endothelial cells as antiangiogenic factor per se 
and that the effect of PEDF depends on the cell’s phenotype.  
▬ The finding that PEDF serum concentrations changed with age and that blood 
cells are able to produce PEDF as well could possibly help in the early 
detection of diseases in which PEDF serum levels vary.  
▬ This study demonstrates for the first time that with increasing maturity of the 
brain, PEDF is localized in neurons of most brain areas until old age, 
suggesting a neuroprotective role for PEDF even at high age.  
▬ Interestingly, PEDF was located in two different neurogenic zones of the brain, 
suggesting that PEDF might be able to also modulate neurogenesis.  
▬ The finding that apart from neuronal and endothelial cells additional cell types 
were immunopositive for PEDF -that were not of astrocytic and 
oligodendrocytic origin-, together with the localization of PEDF in many 
specific –so far not described- areas of the adult brain, open the possibility to 
find other important effects of this factor in the CNS.  
 
We are only starting to understand the complex, multifunctional 
aspects of PEDF. The protein is clearly an interesting, multifaceted factor with 
promising therapeutic functions in degenerative diseases of the eye and 
potentially also the brain, as well as in cancer therapy due to its unique 
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combination of neuroprotective, neurotrophic, differentiating and anti-
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